SMT202000673T1 - Composti triciclici sostituiti come inibitori di fgfr - Google Patents

Composti triciclici sostituiti come inibitori di fgfr

Info

Publication number: SMT202000673T1
Authority: SM; San Marino
Prior art keywords: tricyclic compounds; substituted tricyclic; fgfr inhibitors; fgfr; inhibitors
Prior art date: 2012-06-13

Application number

SM20200673T

Other languages

English (en)

Inventor

Wenqing Yao

Chunhong He

Liangxing Wu

Colin Zhang

Yaping Sun

Liang Lu

Ding-Quan Qian

Meizhong Xu

Jincong Zhuo

Original Assignee

Incyte Holdings Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-13

Filing date

2013-06-12

Publication date

2021-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49486650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000673(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-12 Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp

2021-01-05 Publication of SMT202000673T1 publication Critical patent/SMT202000673T1/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pyridine Compounds (AREA)

SM20200673T 2012-06-13 2013-06-12 Composti triciclici sostituiti come inibitori di fgfr SMT202000673T1 (it)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201261659245P	2012-06-13	2012-06-13
US201261691463P	2012-08-21	2012-08-21
US201261740012P	2012-12-20	2012-12-20
US201361774841P	2013-03-08	2013-03-08
EP18198112.7A EP3495367B1 (en)	2012-06-13	2013-06-12	Substituted tricyclic compounds as fgfr inhibitors

Publications (1)

Publication Number	Publication Date
SMT202000673T1 true SMT202000673T1 (it)	2021-01-05

Family

ID=49486650

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SM20200673T SMT202000673T1 (it)	2012-06-13	2013-06-12	Composti triciclici sostituiti come inibitori di fgfr
SM20190040T SMT201900040T1 (it)	2012-06-13	2013-06-12	Composti triciclici sostituiti come inibitori di fgfr
SM20170146T SMT201700146T1 (it)	2012-06-13	2013-06-12	Composti triciclici sostituiti come inibitori di fgfr

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SM20190040T SMT201900040T1 (it)	2012-06-13	2013-06-12	Composti triciclici sostituiti come inibitori di fgfr
SM20170146T SMT201700146T1 (it)	2012-06-13	2013-06-12	Composti triciclici sostituiti come inibitori di fgfr

Country Status (39)

Country	Link
US (6)	US9611267B2 (it)
EP (5)	EP3176170B1 (it)
JP (7)	JP6301321B2 (it)
KR (3)	KR102140426B1 (it)
CN (3)	CN107652289B (it)
AR (1)	AR091424A1 (it)
AU (5)	AU2013287176C1 (it)
BR (1)	BR112014030812B1 (it)
CA (2)	CA3149881A1 (it)
CL (2)	CL2014003355A1 (it)
CO (1)	CO7240375A2 (it)
CY (4)	CY1118744T1 (it)
DK (3)	DK2861595T5 (it)
EA (1)	EA036592B1 (it)
EC (1)	ECSP22091792A (it)
ES (4)	ES2704744T3 (it)
HK (1)	HK1212326A1 (it)
HR (3)	HRP20170430T1 (it)
HU (4)	HUE031916T2 (it)
IL (5)	IL289834B2 (it)
LT (4)	LT2861595T (it)
LU (1)	LUC00222I2 (it)
ME (2)	ME02651B (it)
MX (2)	MX359293B (it)
MY (2)	MY171375A (it)
NL (1)	NL301131I2 (it)
NO (1)	NO2021034I1 (it)
NZ (3)	NZ730134A (it)
PE (2)	PE20190736A1 (it)
PH (2)	PH12019502809B1 (it)
PL (3)	PL3495367T3 (it)
PT (3)	PT3495367T (it)
RS (3)	RS58514B1 (it)
SG (2)	SG11201408238WA (it)
SI (3)	SI2861595T1 (it)
SM (3)	SMT202000673T1 (it)
TW (3)	TWI706953B (it)
UA (2)	UA117347C2 (it)
WO (1)	WO2014007951A2 (it)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SMT202000673T1 (it) *	2012-06-13	2021-01-05	Incyte Holdings Corp	Composti triciclici sostituiti come inibitori di fgfr
MY180688A (en)	2012-06-13	2020-12-07	Hoffmann La Roche	New diazaspirocycloalkane and azaspirocycloalkane
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
BR112015004111A2 (pt)	2012-09-25	2017-07-04	Hoffmann La Roche	novos derivados bicíclicos
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
AR094812A1 (es)	2013-02-20	2015-08-26	Eisai R&D Man Co Ltd	Derivado de piridina monocíclico como inhibidor del fgfr
AR095079A1 (es)	2013-03-12	2015-09-16	Hoffmann La Roche	Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
SG11201508328PA (en)	2013-04-19	2015-11-27	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US9783504B2 (en)	2013-07-09	2017-10-10	Dana-Farber Cancer Institute, Inc.	Kinase inhibitors for the treatment of disease
WO2015078803A1 (en)	2013-11-26	2015-06-04	F. Hoffmann-La Roche Ag	NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL
PH12020552066A1 (en) *	2014-02-13	2022-05-11	Incyte Corp	Cyclopropylamines as lsd1 inhibitors
AU2015238541B2 (en)	2014-03-26	2019-09-19	F. Hoffmann-La Roche Ag	Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
AU2015238537B2 (en)	2014-03-26	2019-08-01	F. Hoffmann-La Roche Ag	Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
SI3179991T1 (sl)	2014-08-11	2022-04-29	Acerta Pharma B.V.	Terapevtske kombinacije zaviralca BTK in zaviralca BCL-2
ES2921875T3 (es)	2014-08-11	2022-09-01	Acerta Pharma Bv	Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
WO2016024232A1 (en)	2014-08-11	2016-02-18	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
CA2956270C (en)	2014-08-18	2022-08-09	Eisai R&D Management Co., Ltd.	Salt of monocyclic pyridine derivative and crystal thereof
US9255096B1 (en)	2014-10-07	2016-02-09	Allergan, Inc.	Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016064960A1 (en) *	2014-10-22	2016-04-28	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
US9694084B2 (en)	2014-12-23	2017-07-04	Dana-Farber Cancer Institute, Inc.	Methods to induce targeted protein degradation through bifunctional molecules
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
UA121669C2 (uk)	2015-02-20	2020-07-10	Інсайт Корпорейшн	Біциклічні гетероцикли як інгібітори fgfr
MA41898A (fr)	2015-04-10	2018-02-13	Hoffmann La Roche	Dérivés de quinazolinone bicyclique
CA2992889A1 (en)	2015-09-04	2017-03-09	F. Hoffmann-La Roche Ag	Phenoxymethyl derivatives
CR20180143A (es)	2015-09-24	2018-05-03	Hoffmann La Roche	Nuevos compuestos biciclicos como inhibidores duales de atx/ca
BR112018006034A2 (pt)	2015-09-24	2018-10-09	Hoffmann La Roche	compostos bicíclicos como inibidores de atx
CA2991612A1 (en)	2015-09-24	2017-03-30	F. Hoffmann-La Roche Ag	New bicyclic compounds as dual atx/ca inhibitors
BR112018006024A2 (pt)	2015-09-24	2020-05-12	F. Hoffmann-La Roche Ag	Compostos bicíclicos como inibidores de atx
CN107459519A (zh)	2016-06-06	2017-12-12	上海艾力斯医药科技有限公司	稠合嘧啶哌啶环衍生物及其制备方法和应用
JP7090099B2 (ja)	2017-03-16	2022-06-23	エフ．ホフマン－ラロシュアーゲー	Ａｔｘインヒビターとしての新規二環式化合物
CN110392679B (zh)	2017-03-16	2023-04-07	豪夫迈·罗氏有限公司	可用作双重atx/ca抑制剂的杂环化合物
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11760934B2 (en)	2017-11-17	2023-09-19	Dic Corporation	Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used
CN111770909B (zh)	2018-03-01	2024-01-30	Dic株式会社	聚合性化合物以及使用其的液晶组合物和液晶显示元件
CA3091153A1 (en)	2018-03-28	2019-10-03	Eisai R&D Management Co., Ltd.	Therapeutic agent for hepatocellular carcinoma
CN110386932A (zh) *	2018-04-20	2019-10-29	艾科思莱德制药公司	用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
FI3788047T3 (fi)	2018-05-04	2024-11-02	Incyte Corp	Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CA3224985A1 (en)	2018-07-31	2020-02-06	Loxo Oncology, Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
AU2019362849A1 (en) *	2018-10-16	2021-03-11	Dana-Farber Cancer Institute, Inc.	Azaindole inhibitors of wild-type and mutant forms of LRRK2
CN113490666A (zh)	2018-12-19	2021-10-08	奥瑞生物药品公司	作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
JP2022515197A (ja)	2018-12-19	2022-02-17	アレイバイオファーマインコーポレイテッド	がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2020188015A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN109939110A (zh) *	2019-05-08	2019-06-28	湖南中医药大学	药根碱在制备抗血栓药物中的应用
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4011868B1 (en) *	2019-08-08	2025-01-01	Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.	Pyrazine-2(1h)-ketone compound preparation method
WO2021023192A1 (zh) *	2019-08-08	2021-02-11	漳州片仔癀药业股份有限公司	吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
KR20220047810A (ko) *	2019-08-15	2022-04-19	블랙 다이아몬드 테라퓨틱스, 인코포레이티드	알키닐 퀴나졸린 화합물
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar)	2019-10-14	2023-01-30	Incyte Corp	حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
PE20221504A1 (es)	2019-12-04	2022-09-30	Incyte Corp	Derivados de un inhibidor de fgfr
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
MX2023000056A (es)	2020-07-02	2023-04-12	Incyte Corp	Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
WO2022193227A1 (en) *	2021-03-18	2022-09-22	Nutshell Biotech (Shanghai) Co., Ltd.	Fused ring compounds as inhibitors of fgfr tyrosine kinases
EP4323405A1 (en)	2021-04-12	2024-02-21	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
JP2024522189A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4436578A1 (en)	2021-11-22	2024-10-02	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023195018A1 (en) *	2022-04-05	2023-10-12	Msn Laboratories Private Limited, R&D Center	Solid dispersions of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
WO2024206858A1 (en)	2023-03-30	2024-10-03	Revolution Medicines, Inc.	Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en)	2023-05-04	2024-11-07	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
US11884667B1 (en)	2023-07-13	2024-01-30	King Faisal University	Substituted pyrrolo[2,3-c][2,7]naphthyridines as CK2 inhibitors
US11897883B1 (en)	2023-09-01	2024-02-13	King Faisal University	Pyrrolo[3,2-c][1,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891377B1 (en)	2023-09-06	2024-02-06	King Faisal University	Pyrrolo[3,2-c][2,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11866437B1 (en)	2023-09-15	2024-01-09	King Faisal University	1,2-dioxo-2,3-dihydro-1H-pyrrolo[2,3-c]quinoline-7-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (813)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE280853C (it)
US850370A (en)	1906-06-05	1907-04-16	William L Hynes	Water-automobile.
DE2156720A1 (de)	1971-11-16	1973-05-24	Bayer Ag	Pyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine
US3984021A (en)	1972-09-11	1976-10-05	Uhlig Gerhardt E	Safety closure container
US3894021A (en)	1974-01-28	1975-07-08	Squibb & Sons Inc	Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (it)	1974-06-19	1976-06-25
US4347348A (en)	1978-06-05	1982-08-31	Chernikhov Alexei Y	Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (fr)	1978-06-13	1980-01-11	Chernikhov Alexei	Polymeres heterocycliques thermostables et leurs procedes de preparation
CH641470A5 (de)	1978-08-30	1984-02-29	Ciba Geigy Ag	Imidgruppen enthaltende silane.
CH635828A5 (de)	1978-08-30	1983-04-29	Ciba Geigy Ag	N-substituierte imide und bisimide.
US4339267A (en)	1980-01-18	1982-07-13	E. I. Du Pont De Nemours And Company	Herbicidal sulfonamides
US4405520A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4402878A (en)	1980-10-22	1983-09-06	Plastics Engineering Company	Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
US4405786A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405519A (en)	1980-10-22	1983-09-20	Plastics Engineering Company	Di-Acetylene-terminated polyimide derivatives
US4460773A (en)	1982-02-05	1984-07-17	Lion Corporation	1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
DE3432983A1 (de)	1983-09-07	1985-04-18	Lion Corp., Tokio/Tokyo	1,5-disubstituierte 1h-pyrazolo(3,4-b)-pyrazin-derivate und antitumormittel, die diese enthalten
JPS62273979A (ja)	1986-05-21	1987-11-28	Lion Corp	１，５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
JPS6310630A (ja)	1986-06-23	1988-01-18	Teijin Ltd	芳香族ポリアミドイミドエ−テルの製造法
JPS6317882A (ja)	1986-07-09	1988-01-25	Lion Corp	５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
US4859672A (en)	1986-10-29	1989-08-22	Rorer Pharmaceutical Corporation	Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en)	1987-09-21	1989-10-17	Pennwalt Corporation	Dianhydride coupled polymer stabilizers
DE3814549A1 (de)	1987-10-30	1989-05-18	Bayer Ag	N-substituierte derivate von 1-desoxynojirimycin und 1-desoxymannonojirimycin, verfahren zu deren herstellung und deren verwendung in arzneimitteln
JPH029895A (ja)	1988-06-28	1990-01-12	Lion Corp	ヌクレオシド類似化合物及び抗腫瘍剤
DD280853A1 (de)	1989-03-21	1990-07-18	Akad Nauk Sssr	Bindemittel fuer elektroden, vorzugsweise fuer polymerelektroden
US5159054A (en)	1989-05-16	1992-10-27	The United States Of America As Represented By The Secretary Of The Navy	Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (ja)	1989-07-17	1999-01-13	三井化学株式会社	イミド環を有する新規ジフェノール類およびその製造方法
US5726302A (en)	1989-09-15	1998-03-10	Gensia Inc.	Water soluble adenosine kinase inhibitors
DE3937633A1 (de)	1989-11-11	1991-05-16	Bayer Ag	Heterocyclische verbindungen und deren verwendung als pigmente und farbstoffe
WO1991010172A1 (de)	1989-12-28	1991-07-11	Hoechst Aktiengesellschaft	Biskationische säureamid- und -imidderivate als ladungssteuermittel
CA2072597C (en)	1989-12-28	1998-09-22	Hans-Tobias Macholdt	Biscationic acid amide and imide derivatives and processes for their preparation
JP2883670B2 (ja)	1990-03-23	1999-04-19	三井化学株式会社	イミド環を有する新規ビスフェノール類およびその製造方法
GB9113137D0 (en)	1990-07-13	1991-08-07	Ici Plc	Thioxo heterocycles
ATE175665T1 (de)	1990-10-03	1999-01-15	Commw Scient Ind Res Org	Epoxydharze auf basis von diaminobisimidverbindungen
JPH04158084A (ja)	1990-10-22	1992-06-01	Fuji Photo Film Co Ltd	記録材料
JPH04179576A (ja)	1990-11-14	1992-06-26	Fuji Photo Film Co Ltd	記録材料
JPH04328121A (ja)	1991-04-26	1992-11-17	Sumitomo Bakelite Co Ltd	半導体封止用エポキシ樹脂組成物
JP3147902B2 (ja)	1991-06-14	2001-03-19	ファルマシア・アンド・アップジョン・カンパニー	イミダゾ〔１，５−ａ〕キノキサリン
DE4119767A1 (de)	1991-06-15	1992-12-17	Dresden Arzneimittel	Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (ja)	1992-05-18	2002-04-30	鐘淵化学工業株式会社	ヒドロシリル基含有イミド化合物
JP3232123B2 (ja)	1992-05-20	2001-11-26	鐘淵化学工業株式会社	硬化性組成物
CA2136606A1 (en)	1992-05-28	1993-11-29	Trevor C. Morton	Bismaleimide compounds
NZ258488A (en)	1992-12-07	1997-02-24	Commw Scient Ind Res Org	Preparation of bisnadimides (n,n'-bis(aryl)aryl diimides) from an n,n'-bis (aminoaryl)aryldiimide and nadic acid; curable compositions and fibre reinforced cured composites
JPH08506189A (ja)	1993-01-11	1996-07-02	ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア	非線形光学的性質を有する多環式芳香族化合物
WO1994025438A1 (en)	1993-04-28	1994-11-10	The Du Pont Merck Pharmaceutical Company	Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en)	1993-08-25	1996-07-16	Fmc Corporation	Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
PT731795E (pt)	1993-11-30	2000-05-31	Searle & Co	Pirazolilbenzenossulfonamidas para o tratamento de inflamacoes
US5480887A (en)	1994-02-02	1996-01-02	Eli Lilly And Company	Protease inhibitors
WO1995020965A1 (en)	1994-02-02	1995-08-10	Eli Lilly And Company	Hiv protease inhibitors and intermediates
WO1996015128A2 (en)	1994-11-14	1996-05-23	Warner-Lambert Company	6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
US7067664B1 (en)	1995-06-06	2006-06-27	Pfizer Inc.	Corticotropin releasing factor antagonists
US5783577A (en)	1995-09-15	1998-07-21	Trega Biosciences, Inc.	Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (ja)	1996-01-11	1997-07-22	Mitsui Toatsu Chem Inc	結晶化促進剤
WO1997047601A1 (fr)	1996-06-11	1997-12-18	Yoshitomi Pharmaceutical Industries, Ltd.	Composes heterocycliques fusionnes et leurs utilisations medicinales
JP3345021B2 (ja)	1996-08-06	2002-11-18	ファイザーインク．	置換ピリド―またはピリミド―含有６，６―または６，７―二環式誘導体
EP0927167A1 (en)	1996-08-14	1999-07-07	Warner-Lambert Company	2-phenyl benzimidazole derivatives as mcp-1 antagonists
JP3669783B2 (ja)	1996-08-21	2005-07-13	三井化学株式会社	有機電界発光素子
US5994364A (en)	1996-09-13	1999-11-30	Schering Corporation	Tricyclic antitumor farnesyl protein transferase inhibitors
WO1998018781A2 (en)	1996-10-28	1998-05-07	Versicor, Inc.	Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
WO1998028281A1 (en)	1996-12-23	1998-07-02	Celltech Therapeutics Limited	Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
BR9807305A (pt)	1997-02-05	2000-05-02	Warner Lambert Co	Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
CA2285263C (en)	1997-04-11	2009-03-10	Abbott Laboratories	Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
WO1998054156A1 (en)	1997-05-28	1998-12-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
GB9716231D0 (en)	1997-07-31	1997-10-08	Amersham Int Ltd	Base analogues
EP0994892A1 (en)	1997-08-11	2000-04-26	Cor Therapeutics, Inc.	SELECTIVE FACTOR Xa INHIBITORS
EP1003745B1 (en)	1997-08-20	2004-12-29	Warner-Lambert Company Llc	Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6465484B1 (en)	1997-09-26	2002-10-15	Merck & Co., Inc.	Angiogenesis inhibitors
JPH11171865A (ja)	1997-12-04	1999-06-29	Yoshitomi Pharmaceut Ind Ltd	縮合ヘテロ環化合物
CA2316944A1 (en)	1998-02-20	1999-08-26	Mitsuru Shiraishi	Aminoguanidinehydrazone derivative, production and use thereof
EP1077946A1 (en)	1998-05-15	2001-02-28	Guilford Pharmaceuticals Inc.	Fused tricyclic compounds which inhibit parp activity
GEP20033093B (en) *	1998-05-26	2003-10-27	Warner Lambert Co	Bicyclic Pyrimidines and Bicyclic 3,4-Dihydropyrimidines as Inhibitors of Cellular Proliferation, Compositions Containing Them and Methods for Treating Cell Proliferative Disorders
US20040044012A1 (en)	1998-05-26	2004-03-04	Dobrusin Ellen Myra	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU4429799A (en)	1998-06-12	1999-12-30	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
BR9912938B1 (pt)	1998-08-11	2011-06-28		derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
JP2000123973A (ja)	1998-10-09	2000-04-28	Canon Inc	有機発光素子
GB9823103D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
ES2228123T3 (es)	1998-10-23	2005-04-01	F. Hoffmann-La Roche Ag	Heterociclos de nitrogeno biciclicos.
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
DE19912638A1 (de)	1999-03-20	2000-09-21	Bayer Ag	Naphthylcarbonsäureamid-substituierte Sulfonamide
DE19920790A1 (de)	1999-05-06	2000-11-09	Bayer Ag	Bis-Sulfonamide mit anti-HCMV-Wirkung
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP4041624B2 (ja)	1999-07-21	2008-01-30	三井化学株式会社	有機電界発光素子
AP1639A (en)	1999-09-24	2006-07-24	Janssen Pharmaceutica Nv	Pharmaceutical compositions of antiviral compounds and processes for preparation.
DE19946289A1 (de)	1999-09-28	2001-03-29	Basf Ag	Benzodiazepin-Derivate, deren Herstellung und Anwendung
AU776250B2 (en)	1999-10-21	2004-09-02	F. Hoffmann-La Roche Ag	Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
TR200201058T2 (tr)	1999-10-21	2002-07-22	F.Hoffmann-La Roche Ag	P38 protein kinaz inhibitörleri olarak, alkilaminoyla ornatılmış bisiklik, azotlu heterosikller
TWI271406B (en)	1999-12-13	2007-01-21	Eisai Co Ltd	Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
ES2281372T3 (es)	1999-12-29	2007-10-01	Wyeth	Inhibidores de proteina-quinasa triciclicos.
YU55902A (sh)	2000-01-24	2006-01-16	Warner-Lambert Company	3-aminohinazolin-2,4-dioni kao antibakterijska sredstva
CA2394525A1 (en)	2000-01-27	2001-08-02	Warner-Lambert Company	Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
AU2001240542A1 (en)	2000-02-01	2001-08-14	Basf Aktiengesellschaft	Heterocyclic compounds and their use as parp inhibitors
EP1257550B1 (en)	2000-02-04	2005-11-16	Portola Pharmaceuticals, Inc.	Platelet adp receptor inhibitors
ATE295365T1 (de)	2000-02-09	2005-05-15	Novartis Pharma Gmbh	Pyridinderivative als angiogenese- und/oder vegf- rezeptor-tyrosinkinase-inhibitoren
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
DE60112268T2 (de)	2000-03-06	2006-05-24	Astrazeneca Ab	Verwendung von quinazolinderivate als inhibitoren der angiogenese
DE10012549A1 (de)	2000-03-15	2001-09-20	Bayer Ag	Arzneimittel gegen virale Erkrankungen
JP2001265031A (ja)	2000-03-15	2001-09-28	Fuji Xerox Co Ltd	電子写真感光体、プロセスカートリッジ、及び、電子写真装置
KR20030005306A (ko)	2000-04-28	2003-01-17	아카디아 파마슈티칼스 인코포레이티드	무스카린성 작용제
JP2003532728A (ja)	2000-05-05	2003-11-05	コーセラピューティックス，インコーポレイテッド	ヘテロ二環式スルホンアミドおよび血小板ａｄｐレセプターインヒビターとしてのそれらの使用
WO2002000655A1 (en)	2000-06-23	2002-01-03	Bristol-Myers Squibb Pharma Company	1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors
NZ522783A (en)	2000-06-28	2004-07-30	Smithkline Beecham P	Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
US20050009876A1 (en)	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
CA2420967A1 (en)	2000-08-07	2002-02-14	Neurogen Corporation	Heterocyclic compounds as ligands of the gabaa receptor
CZ307185B6 (cs)	2000-08-14	2018-03-07	Ortho Mcneil Pharmaceutical, Inc.	Substituovaný pyrazol, farmaceutická kompozice s jeho obsahem a jejich lékařské aplikace
DE60136546D1 (de)	2000-09-06	2008-12-24	Ortho Mcneil Pharm Inc	Methode zum bekämpfen der allergien durch verwendung von substituierten pyrazolen
GB0025782D0 (en)	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VI
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
WO2002076953A1 (en)	2001-03-21	2002-10-03	Warner-Lambert Company Llc	New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en)	2001-03-23	2006-02-14	Bristol-Myers Squibb Pharma Company	6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (ja)	2001-03-30	2002-10-09	Fuji Photo Film Co Ltd	熱現像カラー画像記録材料
CA2440842A1 (en)	2001-04-16	2002-10-24	Eisai Co., Ltd.	Novel 1h-indazole compounds
WO2002088107A1 (en)	2001-04-26	2002-11-07	Eisai Co., Ltd.	Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
HUP0304054A2 (hu)	2001-04-30	2004-04-28	Glaxo Group Limited	A kortikotropin-realising faktor (CRF) antagonistáiként alkalmazható kondenzált pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
WO2002094825A1 (fr)	2001-05-22	2002-11-28	Banyu Pharmaceutical Co., Ltd.	Nouveau derive de spiropiperidine
US20030114448A1 (en)	2001-05-31	2003-06-19	Millennium Pharmaceuticals, Inc.	Inhibitors of factor Xa
AU2002302894A1 (en)	2001-06-19	2003-01-02	Warner-Lambert Company Llc	Quinazolinediones as antibacterial agents
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
AU2002315389A1 (en)	2001-06-21	2003-01-08	Ariad Pharmaceuticals, Inc.	Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2003000690A1 (en)	2001-06-25	2003-01-03	Aventis Pharmaceuticals Inc.	Synthesis of heterocyclic compounds employing microwave technology
US20040235867A1 (en)	2001-07-24	2004-11-25	Bilodeau Mark T.	Tyrosine kinase inhibitors
PL367983A1 (en)	2001-08-07	2005-03-21	Banyu Pharmaceutical Co, Ltd.	Spiro compounds
CN100391958C (zh)	2001-09-19	2008-06-04	安万特医药股份有限公司	化合物
HU230798B1 (hu)	2001-10-30	2018-06-28	Novartis Ag	Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
NZ531853A (en)	2001-11-01	2006-02-24	Janssen Pharmaceutica Nv	Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
CN1582284A (zh)	2001-11-07	2005-02-16	霍夫曼-拉罗奇有限公司	氨基嘧啶类和吡啶类化合物
CA2466279A1 (en)	2001-11-13	2003-05-22	Dana-Farber Cancer Institute, Inc.	Agents that modulate immune cell activation and methods of use thereof
GB0129476D0 (en)	2001-12-10	2002-01-30	Syngenta Participations Ag	Organic compounds
GEP20063909B (en)	2002-01-22	2006-08-25	Warner Lambert Co	2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
RU2312861C2 (ru)	2002-03-05	2007-12-20	Мерк Фросст Кэнада Лтд.	Ингибиторы катепсин-цистеинпротеазы
US6815519B2 (en)	2002-03-22	2004-11-09	Chung-Shan Institute Of Science & Technology	Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
RU2310657C2 (ru)	2002-04-03	2007-11-20	Ф.Хоффманн-Ля Рош Аг	Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
ES2323952T3 (es)	2002-05-15	2009-07-28	Janssen Pharmaceutica Nv	3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg.
JP4499342B2 (ja)	2002-05-16	2010-07-07	株式会社カネカ	ＳｉＨ基を含有する含窒素有機系化合物の製造方法
AU2003245325A1 (en)	2002-05-23	2003-12-12	Chiron Corporation	Substituted quinazolinone compounds
AR037647A1 (es)	2002-05-29	2004-12-01	Novartis Ag	Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
US7119111B2 (en)	2002-05-29	2006-10-10	Amgen, Inc.	2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
PA8577501A1 (es)	2002-07-25	2004-02-07	Warner Lambert Co	Inhibidores de quinasas
AU2003265336B8 (en)	2002-07-29	2009-04-23	Rigel Pharmaceuticals, Inc.	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2492112A1 (en)	2002-08-06	2004-02-19	F. Hoffmann-La Roche Ag	6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
EP1388541A1 (en)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en)	2002-08-14	2006-08-01	Hoffman-La Roche Inc.	Pyrimido compounds having antiproliferative activity
GB0220187D0 (en)	2002-08-30	2002-10-09	Novartis Ag	Organic compounds
GB0223349D0 (en)	2002-10-08	2002-11-13	Merck Sharp & Dohme	Therapeutic agents
TW200413381A (en)	2002-11-04	2004-08-01	Hoffmann La Roche	Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7112676B2 (en)	2002-11-04	2006-09-26	Hoffmann-La Roche Inc.	Pyrimido compounds having antiproliferative activity
AU2003291310A1 (en)	2002-11-06	2004-06-03	Bristol-Myers Squibb Company	Fused heterocyclic compounds and use thereof
AR042052A1 (es)	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
PL377620A1 (pl)	2002-11-18	2006-02-06	F. Hoffmann-La Roche Ag	Diazynopirymidyny
CA2502970A1 (en)	2002-11-28	2004-06-10	Schering Aktiengesellschaft	Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7244748B2 (en)	2002-12-06	2007-07-17	Purdue Research Foundation	Pyridines for treating injured mammalian nerve tissue
JP4666256B2 (ja)	2002-12-10	2011-04-06	小野薬品工業株式会社	含窒素複素環化合物およびその医薬用途
UA80171C2 (en)	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
US7098332B2 (en)	2002-12-20	2006-08-29	Hoffmann-La Roche Inc.	5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
AU2003288675B2 (en)	2002-12-23	2010-07-22	Medimmune Limited	Antibodies against PD-1 and uses therefor
JP2004203749A (ja)	2002-12-24	2004-07-22	Kanegafuchi Chem Ind Co Ltd	ＳｉＨ基を含有する含窒素有機系化合物の製造方法
DE602004021558D1 (de)	2003-01-17	2009-07-30	Warner Lambert Co	2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
US7135469B2 (en)	2003-03-18	2006-11-14	Bristol Myers Squibb, Co.	Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
US20040242566A1 (en)	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
RU2350617C2 (ru)	2003-04-10	2009-03-27	Ф.Хоффманн-Ля Рош Аг	Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр
CN100372851C (zh)	2003-05-05	2008-03-05	弗·哈夫曼-拉罗切有限公司	具有crf活性的稠合的嘧啶衍生物
JP2004346145A (ja)	2003-05-21	2004-12-09	Teijin Ltd	イミド組成物およびそれからなる樹脂組成物、及びその製造方法
JP2007501861A (ja)	2003-05-23	2007-02-01	カイロンコーポレイション	Ｍｃ４−ｒアゴニストとしてのグアニジノ置換キナゾリノン化合物
CA2525383C (en)	2003-06-06	2012-03-06	Arexis Ab	Use of heterocyclic compounds as scce inhibitors
IL156495A0 (en)	2003-06-17	2004-01-04	Prochon Biotech Ltd	Use of fgfr3 antagonists for treating t cell mediated diseases
WO2004113307A1 (ja)	2003-06-18	2004-12-29	Ube Industries, Ltd.	ピリミジン−４−オン化合物の製造方法
JP2005015395A (ja)	2003-06-26	2005-01-20	Japan Science & Technology Agency	新規ピリミドピリミジンヌクレオシドとその構造類縁体
WO2005003100A2 (en)	2003-07-03	2005-01-13	Myriad Genetics, Inc.	4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
AR045037A1 (es)	2003-07-10	2005-10-12	Aventis Pharma Sa	Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US7371750B2 (en)	2003-07-29	2008-05-13	Irm Llc	Compounds and compositions as protein kinase inhibitors
US7390820B2 (en)	2003-08-25	2008-06-24	Amgen Inc.	Substituted quinolinone derivatives and methods of use
EP1675858A2 (en)	2003-09-03	2006-07-05	Neurogen Corporation	5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
US7138401B2 (en)	2003-09-18	2006-11-21	Conforma Therapeutics Corporation	2-aminopurine analogs having HSP90-inhibiting activity
ATE433974T1 (de)	2003-09-19	2009-07-15	Gilead Sciences Inc	Azachinolinolphosphonatverbindungen als integraseinhibitoren
AR045944A1 (es)	2003-09-24	2005-11-16	Novartis Ag	Derivados de isoquinolina 1.4-disustituidas
CA2540647C (en)	2003-10-01	2012-07-10	Bayer Healthcare Ag	Tetrahydro-naphthalene and urea derivatives
US7449582B2 (en) *	2003-10-08	2008-11-11	Irm Llc	Compounds and compositions as protein kinase inhibitors
CN1897950A (zh)	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
WO2005047289A1 (en)	2003-11-17	2005-05-26	Pfizer Products Inc.	Pyrrolopyrimidine compounds useful in treatment of cancer
WO2005056524A2 (en)	2003-12-09	2005-06-23	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
US20080188527A1 (en)	2003-12-23	2008-08-07	Cashman John R	Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
KR100703068B1 (ko)	2003-12-30	2007-04-05	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US20050222171A1 (en)	2004-01-22	2005-10-06	Guido Bold	Organic compounds
US20050165032A1 (en)	2004-01-23	2005-07-28	Norman Mark H.	Vanilloid receptor ligands and their use in treatments
DE602005016890D1 (de)	2004-01-23	2009-11-12	Janssen Pharmaceutica Nv	Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
US20060019952A1 (en)	2004-01-29	2006-01-26	Elixir Pharmaceuticals, Inc.	Anti-viral therapeutics
GB0402137D0 (en)	2004-01-30	2004-03-03	Smithkline Beecham Corp	Novel compounds
WO2005080393A1 (en)	2004-02-14	2005-09-01	Irm Llc	Compounds and compositions as protein kinase inhibitors
CA2555724A1 (en)	2004-02-18	2005-09-09	Warner-Lambert Company Llc	2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
CN1926139A (zh)	2004-02-27	2007-03-07	霍夫曼-拉罗奇有限公司	稠合吡唑衍生物
CA2558109A1 (en)	2004-02-27	2005-09-15	F. Hoffmann-La Roche Ag	Heteroaryl-fused pyrazolo derivatives
WO2005087765A1 (en)	2004-03-04	2005-09-22	Arena Pharmaceuticals, Inc.	Ligands of follicle stimulating hormone receptor and methods of use thereof
US20070197510A1 (en)	2004-03-10	2007-08-23	Kazuyuki Ohmoto	Nitriles and medicinal compositions containing the same as the active ingredient
CN1938321B (zh)	2004-03-29	2010-05-05	三井化学株式会社	新型化合物及使用该化合物的有机电子元件
WO2005105097A2 (en) *	2004-04-28	2005-11-10	Gpc Biotech Ag	Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (ja)	2004-05-10	2005-11-17	Mitsui Chemicals Inc	テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
US20050256309A1 (en)	2004-05-12	2005-11-17	Altenbach Robert J	Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
MXPA06013805A (es)	2004-05-27	2007-02-02	Pfizer Prod Inc	Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
US20070254877A1 (en)	2004-06-02	2007-11-01	Takada Pharmaceutical Company Limited	Indole Derivative and Use for Treatment of Cancer
PE20060426A1 (es)	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
AR049511A1 (es)	2004-06-10	2006-08-09	Irm Llc	Compuestos y composiciones como inhibidores de quinasa de proteina
WO2005121142A1 (en)	2004-06-11	2005-12-22	Japan Tobacco Inc.	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
JP2006028027A (ja)	2004-07-12	2006-02-02	Mitsui Chemicals Inc	テトラカルボン酸誘導体、および該化合物を用いた電子写真感光体、電子写真装置
AU2005278959A1 (en)	2004-08-31	2006-03-09	Astrazeneca Ab	Quinazolinone derivatives and their use as B-Raf inhibitors
CA2576924A1 (en)	2004-08-31	2006-03-09	F. Hoffmann-La Roche Ag	Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
US7655651B2 (en)	2004-08-31	2010-02-02	Hoffmann-La Roche Inc.	Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
DE102004042667A1 (de)	2004-09-01	2006-03-30	Ewald Dörken Ag	Mehrschichtige Gebäudewand
TWI370147B (en)	2004-09-10	2012-08-11	Ube Industries	Modified polyimide resin and curable resin composition
CA2584412C (en)	2004-09-14	2017-05-09	Minerva Biotechnologies Corporation	Methods for diagnosis and treatment of cancer
GB0420719D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
WO2006038112A1 (en)	2004-10-01	2006-04-13	Warner-Lambert Company Llc	Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (fr)	2004-10-15	2007-01-05	Centre Nat Rech Scient Cnrse	Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20060135553A1 (en)	2004-10-28	2006-06-22	Campbell David A	Imidazole derivatives
WO2006050076A1 (en)	2004-10-29	2006-05-11	Janssen Pharmaceutica, N.V.	Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
MX2007005434A (es)	2004-11-08	2007-07-10	Baxter Int	Composiciones de nanoparticulado de inhibidor de tubulina.
MX2007005820A (es)	2004-11-18	2007-07-18	Incyte Corp	Inhibidores de deshidrogenasa esteroide hidroxilo 11-beta tipo 1 y metodos de uso de los mismos.
KR20070089201A (ko)	2004-11-22	2007-08-30	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피롤로피라진 및피라졸로피라진
AU2005309019A1 (en)	2004-11-24	2006-06-01	Novartis Ag	Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
MY140748A (en)	2004-12-06	2010-01-15	Astrazeneca Ab	Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EP1828186A1 (en)	2004-12-13	2007-09-05	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
WO2006074293A2 (en)	2005-01-07	2006-07-13	President And Fellows Of Harvard College	Bicyclic dihydropyrimidines as eg5 inhibitors
DE102005008310A1 (de)	2005-02-17	2006-08-24	Schering Ag	Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
BRPI0607402A2 (pt)	2005-03-01	2009-09-01	Pfizer Ltd	uso de inibidores de pde7 para o tratamento de dor neuropática
US7297700B2 (en)	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006105448A2 (en)	2005-03-30	2006-10-05	Minerva Biotechnologies Corporation	Proliferation of muc1 expressing cells
JP2006284843A (ja)	2005-03-31	2006-10-19	Mitsui Chemicals Inc	テトラカルボン酸誘導体を用いた電子写真感光体、電子写真装置
US20060223993A1 (en)	2005-04-01	2006-10-05	Connor Daniel M	Colorant compounds, intermediates, and compositions
JP2006316054A (ja)	2005-04-15	2006-11-24	Tanabe Seiyaku Co Ltd	高コンダクタンス型カルシウム感受性ｋチャネル開口薬
KR100781704B1 (ko)	2005-04-20	2007-12-03	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
WO2006119504A2 (en)	2005-05-04	2006-11-09	Renovis, Inc.	Fused heterocyclic compounds, and compositions and uses thereof
EP2418278A3 (en)	2005-05-09	2012-07-04	Ono Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2006124731A2 (en) *	2005-05-12	2006-11-23	Irm Llc	Compounds and compositions as protein kinase inhibitors
EP1891066B1 (en)	2005-05-13	2010-12-22	Irm, Llc	Compounds and compositions as protein kinase inhibitors
US20060279115A1 (en)	2005-06-09	2006-12-14	Ash Tisdelle	Vehicular head and neck safety system and method
GB0512844D0 (en)	2005-06-23	2005-08-03	Novartis Ag	Organic compounds
EP2982379A1 (en)	2005-07-01	2016-02-10	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1915377A1 (en)	2005-07-22	2008-04-30	Sunesis Pharmaceuticals, Inc.	Pyrazolo pyrimidines useful as aurora kinase inhibitors
EP1910369A1 (en)	2005-07-29	2008-04-16	Astellas Pharma Inc.	Fused heterocycles as lck inhibitors
ES2270715B1 (es)	2005-07-29	2008-04-01	Laboratorios Almirall S.A.	Nuevos derivados de pirazina.
RU2008108898A (ru)	2005-08-09	2009-09-20	Айрм Ллк (Bm)	Соединения и композиции в качестве ингибиторов протеинкиназы
KR20080035698A (ko)	2005-08-16	2008-04-23	아이알엠 엘엘씨	단백질 키나제 억제제로서의 화합물 및 조성물
EP1919470A1 (en)	2005-08-25	2008-05-14	F.Hoffmann-La Roche Ag	FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
US7678917B2 (en)	2005-09-01	2010-03-16	Hoffman-La Roche Inc.	Factor Xa inhibitors
MX2008003172A (es)	2005-09-06	2008-03-18	Smithkline Beecham Corp	Proceso regioselectivo para la preparacion de bencimidazol-tiofenos.
WO2007032466A1 (ja)	2005-09-15	2007-03-22	Aska Pharmaceutical Co., Ltd.	複素環化合物、その製造方法並びに用途
US20070116984A1 (en)	2005-09-21	2007-05-24	Doosan Corporation	Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
WO2007038209A2 (en)	2005-09-23	2007-04-05	Schering Corporation	Fused tetracyclic mglur1 antagonists as therapeutic agents
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
AU2006302179C1 (en)	2005-10-07	2013-06-20	Exelixis, Inc.	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CA2624965A1 (en)	2005-10-07	2007-04-19	Exelixis, Inc.	Pyridopyrimidinone inhibitors of pi3k.alpha.
WO2007061554A2 (en)	2005-10-21	2007-05-31	Purdue Research Foundation	Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
TW200800220A (en)	2005-10-26	2008-01-01	Boehringer Ingelheim Int	New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
JP5191391B2 (ja)	2005-11-01	2013-05-08	ターゲジェンインコーポレーティッド	キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8067457B2 (en)	2005-11-01	2011-11-29	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of CCR2
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
ES2401099T3 (es)	2005-11-02	2013-04-16	Bayer Intellectual Property Gmbh	Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
WO2007056075A2 (en)	2005-11-02	2007-05-18	Targegen, Inc.	Six membered heteroaromatic inhibitors targeting resistant kinase mutations
DK1954274T3 (da)	2005-11-10	2011-01-31	Chemocentryx Inc	Substituerede quinoloner og fremgangsmåder til anvendelse
MY146564A (en)	2005-11-10	2012-08-30	Msd Kk	Aza-substituted spiro derivatives
WO2007058626A1 (en)	2005-11-16	2007-05-24	S*Bio Pte Ltd	Indazole compounds
WO2007058392A1 (ja)	2005-11-21	2007-05-24	Japan Tobacco Inc.	ヘテロ環化合物およびその医薬用途
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN101466710B (zh)	2005-12-02	2013-05-29	拜尔健康护理有限责任公司	用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
CN101365682A (zh)	2005-12-08	2009-02-11	千禧药品公司	具有激酶抑制活性的双环化合物
WO2007066189A2 (en)	2005-12-09	2007-06-14	Pfizer Products Inc.	Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
JP2009520038A (ja)	2005-12-19	2009-05-21	ジェネンテック・インコーポレーテッド	ピリミジンキナーゼインヒビター
CA2634047C (en)	2005-12-21	2016-04-12	Novartis Ag	Pyrimidinyl aryl urea derivatives being fgf inhibitors
WO2007084314A2 (en)	2006-01-12	2007-07-26	Incyte Corporation	MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
PE20071025A1 (es)	2006-01-31	2007-10-17	Mitsubishi Tanabe Pharma Corp	Compuesto amina trisustituido
US7427625B2 (en)	2006-02-08	2008-09-23	Janssen Pharmaceutica, N.V.	Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
WO2007093901A1 (en)	2006-02-17	2007-08-23	Pfizer Limited	3 -deazapurine derivatives as tlr7 modulators
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US8349850B2 (en)	2006-03-28	2013-01-08	Atir Holding S.A.	Heterocyclic compounds and uses thereof in the treatment of sexual disorders
CA2647543A1 (en)	2006-03-29	2007-11-08	Foldrx Pharmaceuticals, Inc.	Inhibition of alpha-synuclein toxicity
AU2007234717B2 (en)	2006-04-06	2012-04-19	Wisconsin Alumni Research Foundation	2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
US20090286813A1 (en)	2006-04-13	2009-11-19	Astrazeneca Ab	Thioxanthine Derivatives and Their Use as Inhibitors of MPO
GB0608386D0 (en)	2006-04-27	2006-06-07	Senexis Ltd	Compounds
WO2007125405A2 (en)	2006-05-01	2007-11-08	Pfizer Products Inc.	Substituted 2-amino-fused heterocyclic compounds
CN101437822B (zh) *	2006-05-11	2012-11-28	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
AU2007254491A1 (en)	2006-05-15	2007-11-29	Irm Llc	Compositions and methods for FGF receptor kinases inhibitors
WO2007143600A2 (en)	2006-06-05	2007-12-13	Incyte Corporation	Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
DE102006027156A1 (de)	2006-06-08	2007-12-13	Bayer Schering Pharma Ag	Sulfimide als Proteinkinaseinhibitoren
WO2007147217A1 (en)	2006-06-22	2007-12-27	Prana Biotechnology Limited	Method of treatment of glioma brain tumour
WO2008005877A2 (en)	2006-06-30	2008-01-10	Board Of Regents, The University Of Texas System	Inhibitors of c-kit and uses thereof
MX2008016523A (es)	2006-06-30	2009-01-19	Astrazeneca Ab	Derivados de pirimidina utiles en el tratamiento de cancer.
JP2009542604A (ja)	2006-07-06	2009-12-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
WO2008008234A1 (en)	2006-07-07	2008-01-17	Targegen, Inc.	2-amino-5-substituted pyrimidine inhibitors
TW200811134A (en)	2006-07-12	2008-03-01	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en)	2006-07-26	2008-01-31	Pfizer Products Inc.	Amine derivatives useful as anticancer agents
JP2010500372A (ja)	2006-08-09	2010-01-07	スミスクラインビーチャムコーポレーション	オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
WO2008021389A2 (en)	2006-08-16	2008-02-21	Exelixis, Inc.	Using pi3k and mek modulators in treatments of cancer
DE102006041382A1 (de)	2006-08-29	2008-03-20	Bayer Schering Pharma Ag	Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
BRPI0719123A2 (pt)	2006-09-01	2013-12-17	Cylene Pharmaceuticals Inc	Moduladores de serina-treonina proteína cinase e parp
CA2662677C (en)	2006-09-05	2016-05-31	Emory University	Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
JP2010502751A (ja)	2006-09-11	2010-01-28	シージーアイファーマシューティカルズ，インコーポレイティド	キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
WO2008034859A1 (en)	2006-09-21	2008-03-27	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US20080176891A1 (en)	2006-09-22	2008-07-24	Paul Bamborough	Novel compounds
RU2009115784A (ru)	2006-09-28	2010-11-10	Новартис АГ (CH)	Производные пиразоло[1,5-а]пиримидина и их применение в медицине
BRPI0719797A8 (pt)	2006-10-02	2017-12-26	Novartis Ag	Compostos e composições como inibidores de proteína cinase
AR063420A1 (es)	2006-10-30	2009-01-28	Glaxo Group Ltd	Derivados de 2-ciano-4-pirimidinil sustituidos,proceso de preparacion de los mismos,medicamentos que los contienen y su uso para el tratamiento de la malaria.
US7858645B2 (en)	2006-11-01	2010-12-28	Hoffmann-La Roche Inc.	Indazole derivatives
CN101600714B (zh)	2006-11-10	2013-08-21	百时美施贵宝公司	吡咯并吡啶激酶抑制剂
US7892454B2 (en)	2006-11-17	2011-02-22	Polyera Corporation	Acene-based organic semiconductor materials and methods of preparing and using the same
WO2008063609A2 (en)	2006-11-17	2008-05-29	Polyera Corporation	Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (ko)	2006-11-20	2008-05-23	에스케이케미칼주식회사	피리딘 화합물을 포함하는 간염 치료 및 예방 또는 간 보호효능을 갖는 약제 조성물
SI3034075T1 (sl)	2006-11-22	2018-12-31	Incyte Holdings Corporation	Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
WO2008076278A2 (en)	2006-12-13	2008-06-26	Schering Corporation	Methods of cancer treatment with igf1r inhibitors
WO2008071455A1 (en)	2006-12-15	2008-06-19	Bayer Schering Pharma Aktiengesellschaft	Bicyclic acyltryptophanols
WO2008074068A1 (en)	2006-12-20	2008-06-26	Prana Biotechnology Limited	Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CA2672213C (en)	2006-12-22	2016-02-16	Astex Therapeutics Limited	Bicyclic amine derivatives as protein tyrosine kinase inhibitors
AU2007336933A1 (en)	2006-12-22	2008-07-03	Novartis Ag	Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
EP2114941B1 (en)	2006-12-22	2015-03-25	Astex Therapeutics Limited	Bicyclic heterocyclic compounds as fgfr inhibitors
FR2911140B1 (fr)	2007-01-05	2009-02-20	Sanofi Aventis Sa	Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2104676A2 (en)	2007-01-08	2009-09-30	Polyera Corporation	Methods for preparing arene-bis(dicarboximide)-based semiconducting materials and related intermediates for preparing same
CN101007778A (zh)	2007-01-10	2007-08-01	复旦大学	一种链延长型芴基双马来酰亚胺及其制备方法
JP2010515760A (ja)	2007-01-12	2010-05-13	バイオクライストファーマシューティカルズ，インコーポレイテッド	抗ウイルス性ヌクレオシド類似体
JP5287253B2 (ja)	2007-01-12	2013-09-11	アステラス製薬株式会社	縮合ピリジン化合物
FR2911604B1 (fr)	2007-01-19	2009-04-17	Sanofi Aventis Sa	Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP5358962B2 (ja)	2007-02-06	2013-12-04	住友化学株式会社	組成物及び該組成物を用いてなる発光素子
JP2008198769A (ja)	2007-02-13	2008-08-28	Nippon Steel Chem Co Ltd	有機エレクトロルミネッセント素子
JP5390407B2 (ja)	2007-03-06	2014-01-15	ノバルティスアーゲー	炎症またはアレルギー症状の処置に適する二環式有機化合物
US7691851B2 (en)	2007-03-07	2010-04-06	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors containing a heterocyclic moiety
WO2008109943A1 (en)	2007-03-12	2008-09-18	Cytopia Research Pty Ltd	Phenyl amino pyrimidine compounds and uses thereof
CA2679980A1 (en)	2007-03-21	2007-09-27	Epix Pharmaceuticals, Inc.	S1p receptor modulating compounds and use thereof
US20080234262A1 (en)	2007-03-21	2008-09-25	Wyeth	Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
CA2680783C (en)	2007-03-23	2012-04-24	Amgen Inc.	Heterocyclic compounds and their uses
EP2896624B1 (en)	2007-03-28	2016-07-13	Atir Holding S.A.	Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
KR20080091948A (ko)	2007-04-10	2008-10-15	에스케이케미칼주식회사	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
KR20100016477A (ko)	2007-04-12	2010-02-12	어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드	Ａｌｄ/ｃｖｄ용의 지르코늄, 하프늄, 티타늄 및 규소 전구체
US8318751B2 (en)	2007-04-20	2012-11-27	Merck Sharp & Dohme Corp.	Pyrimidinone derivatives and methods of use thereof
EP1985612A1 (en)	2007-04-26	2008-10-29	Bayer Schering Pharma Aktiengesellschaft	Arymethylen substituted N-Acyl-gamma-aminoalcohols
EP1990342A1 (en)	2007-05-10	2008-11-12	AEterna Zentaris GmbH	Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
TW200902008A (en)	2007-05-10	2009-01-16	Smithkline Beecham Corp	Quinoxaline derivatives as PI3 kinase inhibitors
WO2008144253A1 (en)	2007-05-14	2008-11-27	Irm Llc	Protein kinase inhibitors and methods for using thereof
GB2449293A (en)	2007-05-17	2008-11-19	Evotec	Compounds having Hsp90 inhibitory activity
CA2689282A1 (en)	2007-06-03	2008-12-11	Vanderbilt University	Benzamide mglur5 positive allosteric modulators and methods of making and using same
CA2689444A1 (en)	2007-06-07	2008-12-18	Merck Sharp & Dohme Corp.	Tricyclic anilide heterocyclic cgrp receptor antagonists
US8633186B2 (en)	2007-06-08	2014-01-21	Senomyx Inc.	Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
KR20100024932A (ko)	2007-06-15	2010-03-08	반유 세이야꾸 가부시끼가이샤	비사이클로아닐린 유도체
PT2170959E (pt)	2007-06-18	2014-01-07	Merck Sharp & Dohme	Anticorpos para o receptor humano de morte programada pd-1
EP2183027B1 (en)	2007-07-26	2011-08-31	Novartis AG	Organic compounds
EP2018859A1 (en)	2007-07-26	2009-01-28	Bayer Schering Pharma Aktiengesellschaft	Arylmethylene substituted N-acyl-beta-amino alcohols
EP2020404A1 (en)	2007-08-01	2009-02-04	Bayer Schering Pharma Aktiengesellschaft	Cyanomethyl substituted N-Acyl Tryptamines
WO2009019518A1 (en)	2007-08-09	2009-02-12	Astrazeneca Ab	Pyrimidine compounds having a fgfr inhibitory effect
EP2173354A4 (en)	2007-08-09	2011-10-05	Glaxosmithkline Llc	CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
US9493419B2 (en)	2007-08-21	2016-11-15	The Hong Kong Polytechnic University	Quinoline derivatives as anti-cancer agents
US7960400B2 (en)	2007-08-27	2011-06-14	Duquesne University Of The Holy Ghost	Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009029625A1 (en)	2007-08-27	2009-03-05	Kalypsys, Inc.	4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
CA2698511C (en)	2007-09-04	2016-10-11	The Scripps Research Institute	Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en)	2007-09-07	2009-03-12	Vernalis R & D Ltd	Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en)	2007-09-10	2009-05-16	Curis Inc	HSP90 inhibitors containing a zinc binding moiety
CN101883777B (zh)	2007-10-01	2015-03-25	Isis制药公司	成纤维细胞生长因子受体4表达的反义调节
US8314094B2 (en)	2007-10-05	2012-11-20	Msd K.K	Benzoxazinone derivative
EP2209775A1 (en)	2007-10-09	2010-07-28	UCB Pharma, S.A.	Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en)	2007-10-10	2009-04-16	Syndax Pharmaceuticals, Inc.	Novel compounds and methods of using them
CN101821243B (zh)	2007-10-11	2013-05-08	中国科学院上海药物研究所	一类嘧啶取代苯丙酸衍生物及其作为ppar激动剂的用途
GB0720038D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New compounds
GB0720041D0 (en)	2007-10-12	2007-11-21	Astex Therapeutics Ltd	New Compounds
JP5273052B2 (ja)	2007-10-13	2013-08-28	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
WO2009052145A1 (en)	2007-10-16	2009-04-23	Wyeth	Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
AU2008313773B2 (en)	2007-10-17	2012-04-12	Novartis Ag	Imidazo [1, 2-A] pyridine derivatives useful as ALK inhibitors
KR20100089090A (ko)	2007-10-25	2010-08-11	아스트라제네카 아베	세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
RU2007139634A (ru)	2007-10-25	2009-04-27	Сергей Олегович Бачурин (RU)	Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
WO2009056886A1 (en)	2007-11-01	2009-05-07	Astrazeneca Ab	Pyrimidine derivatives and their use as modulators of fgfr activity
EP3150593B8 (en)	2007-11-28	2019-08-21	Dana Farber Cancer Institute, Inc.	Small molecule myristate inhibitors of bcr-abl and methods of use
CA2707653A1 (en)	2007-12-03	2009-06-11	Boehringer Ingelheim International Gmbh	Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
AU2008343932B2 (en)	2007-12-19	2013-08-15	Amgen Inc.	Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AU2008345225A1 (en)	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
US20100331333A1 (en)	2007-12-21	2010-12-30	Wyeth Llc	Imidazo [1,2-B] Pyridazine Compounds
WO2009086509A2 (en)	2007-12-27	2009-07-09	Purdue Research Foundation	Reagents for biomolecular labeling, detection and quantification employing raman spectroscopy
FR2926297B1 (fr)	2008-01-10	2013-03-08	Centre Nat Rech Scient	Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
JP5584626B2 (ja)	2008-01-24	2014-09-03	アンドレイ・アレクサンドロビッチ・イワシェンコ	２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用
WO2009092764A1 (en)	2008-01-24	2009-07-30	Ucb Pharma, S.A.	Compounds comprising a cyclobutoxy group
WO2009093210A2 (ru)	2008-01-24	2009-07-30	Alla Chem, Llc	ЗАМЕЩЕННЫЕ ЦИKЛOAЛKAHO[e ИЛИ d]ПИPAЗOЛO[l,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US7964608B2 (en)	2008-01-25	2011-06-21	High Point Pharmaceuticals, Llc	Tricyclic compounds as modulators of TNF-α synthesis
JP5608099B2 (ja)	2008-01-30	2014-10-15	ジェネンテック，インコーポレイテッド	ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
EP2265270A1 (en)	2008-02-04	2010-12-29	OSI Pharmaceuticals, Inc.	2-aminopyridine kinase inhibitors
EP2252613A1 (en)	2008-02-22	2010-11-24	Irm, Llc	Compounds and compositions as modulators of gpr119 activity
KR101247840B1 (ko)	2008-02-22	2013-03-26	에프. 호프만-라 로슈 아게	아밀로이드 베타 조절제
US8383629B2 (en)	2008-02-27	2013-02-26	Vitae Pharmaceuticals, Inc.	Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
WO2009108827A1 (en)	2008-02-29	2009-09-03	Wyeth	Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
ITTV20080039A1 (it)	2008-03-06	2009-09-07	Alpinestars Research Srl	Collare di protezione in particolare per guidatori di motoveicoli
WO2009114335A2 (en)	2008-03-12	2009-09-17	Merck & Co., Inc.	Pd-1 binding proteins
GB0804701D0 (en)	2008-03-13	2008-04-16	Amura Therapeutics Ltd	Compounds
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
WO2009146034A2 (en)	2008-03-31	2009-12-03	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof
WO2009122180A1 (en)	2008-04-02	2009-10-08	Medical Research Council	Pyrimidine derivatives capable of inhibiting one or more kinases
US8436005B2 (en)	2008-04-03	2013-05-07	Abbott Laboratories	Macrocyclic pyrimidine derivatives
AU2009233951B2 (en)	2008-04-07	2014-02-27	Amgen Inc.	Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2009124755A1 (en)	2008-04-08	2009-10-15	European Molecular Biology Laboratory (Embl)	Compounds with novel medical uses and method of identifying such compounds
WO2009125809A1 (ja)	2008-04-11	2009-10-15	第一三共株式会社	ピペリジン誘導体
WO2009125808A1 (ja)	2008-04-11	2009-10-15	第一三共株式会社	アミノシクロヘキシル誘導体
EP2444403A1 (en)	2008-04-18	2012-04-25	Shionogi Co., Ltd.	Heterocyclic compound having inhibitory activity on PI3K
CA2723185A1 (en)	2008-04-22	2009-10-29	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
US7863291B2 (en)	2008-04-23	2011-01-04	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en)	2008-04-23	2012-11-13	Bristol-Myers Squibb Company	Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
CN103353532B (zh)	2008-04-29	2016-05-11	诺瓦提斯公司	监测成纤维细胞生长因子受体的激酶活性的调节的方法及所述方法的应用
JP5302389B2 (ja)	2008-04-29	2013-10-02	エフ．ホフマン−ラロシュアーゲー	Ｊｎｋのピリミジニルピリドンインヒビター
WO2009133127A1 (en)	2008-04-30	2009-11-05	Merck Serono S.A.	Fused bicyclic compounds and use thereof as pi3k inhibitors
US9315449B2 (en)	2008-05-15	2016-04-19	Duke University	Substituted pyrazoles as heat shock transcription factor activators
GEP20125502B (en)	2008-05-23	2012-04-25	Novartis Ag	Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2009144205A1 (en)	2008-05-30	2009-12-03	Basf Se	Rylene-based semiconductor materials and methods of preparation and use thereof
AU2009255358A1 (en)	2008-06-03	2009-12-10	Msd K.K.	Inhibitors of Akt activity
KR101656793B1 (ko)	2008-06-10	2016-09-12	유디씨 아일랜드 리미티드	신규한 전이 금속 착물 및 이의 유기 발광 다이오드에서의 용도 - ⅲ
FR2932600B1 (fr)	2008-06-11	2010-06-04	Areva Np	Embout inferieur d'assemblage de combustible nucleaire
ES2430053T3 (es)	2008-06-12	2013-11-18	Merck Sharp & Dohme Corp.	Procedimiento para producir derivados de bicicloanilina
GB0810902D0 (en)	2008-06-13	2008-07-23	Astex Therapeutics Ltd	New compounds
EA201100030A1 (ru)	2008-06-19	2011-08-30	Астразенека Аб	Пиразольные соединения 436
WO2009157423A1 (ja)	2008-06-24	2009-12-30	財団法人乙卯研究所	縮合環を有するオキサゾリジノン誘導体
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ602832A (en)	2008-07-14	2014-04-30	Gilead Sciences Inc	Fused heterocyclic hdac inhibitor compounds
WO2010007099A1 (en)	2008-07-15	2010-01-21	Cellzome Limited	2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
CN102066370B (zh)	2008-07-15	2014-05-14	霍夫曼-拉罗奇有限公司	苯基-咪唑并吡啶类和哒嗪类
UY31982A (es)	2008-07-16	2010-02-26	Boehringer Ingelheim Int	Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
EP2328897A1 (en)	2008-07-16	2011-06-08	Schering Corporation	Bicyclic heterocycle derivatives and their use as gpcr modulators
AU2009270971A1 (en)	2008-07-16	2010-01-21	Schering Corporation	Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
US10722562B2 (en)	2008-07-23	2020-07-28	Immudex Aps	Combinatorial analysis and repair
US8455477B2 (en)	2008-08-05	2013-06-04	Merck Sharp & Dohme Corp.	Therapeutic compounds
AR072906A1 (es)	2008-08-06	2010-09-29	Novartis Ag	Nucleosidos modificados utiles como antivirales
CN102177152A (zh)	2008-08-11	2011-09-07	哈佛大学校长及研究员协会	用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
UY32049A (es)	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
WO2010030027A1 (en)	2008-09-10	2010-03-18	Mitsubishi Tanabe Pharma Corporation	Aromatic nitrogen-containing 6-membered ring compounds and their use
SI2342226T1 (sl)	2008-09-26	2016-11-30	Dana-Farber Cancer Institute Inc.	Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
TW201016676A (en)	2008-10-03	2010-05-01	Astrazeneca Ab	Heterocyclic derivatives and methods of use thereof
WO2010045371A1 (en)	2008-10-15	2010-04-22	Gilead Palo Alto, Inc.	Pyrido- and pyrimido (1, 2-a) pyrimidine compounds useful as stearoyl coa desaturase inhibitors
US8110578B2 (en)	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
UY32203A (es)	2008-10-29	2010-05-31	Astrazeneca Ab	Amino pirimidinas y su uso en terapia
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en)	2008-11-05	2010-05-14	Ucb Pharma S.A.	Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en)	2008-11-18	2010-05-27	Glaxosmithkline Llc	Prolyl hydroxylase inhibitors
AR074199A1 (es)	2008-11-20	2010-12-29	Glaxosmithkline Llc	Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
JP5522053B2 (ja)	2008-12-03	2014-06-18	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101061599B1 (ko)	2008-12-05	2011-09-02	한국과학기술연구원	비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CN106336400A (zh)	2008-12-08	2017-01-18	萌蒂制药国际有限公司	酪氨酸激酶蛋白受体拮抗剂
PT2376535T (pt)	2008-12-09	2017-06-23	Hoffmann La Roche	Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
US8110265B2 (en)	2008-12-09	2012-02-07	The Coca-Cola Company	Pet container and compositions having enhanced mechanical properties and gas barrier properties
WO2010067888A1 (en)	2008-12-12	2010-06-17	Banyu Pharmaceutical Co.,Ltd.	Dihydropyrimidopyrimidine derivatives
AU2009325398A1 (en)	2008-12-12	2010-06-17	Msd K.K.	Dihydropyrimidopyrimidine derivative
ES2544452T3 (es)	2008-12-19	2015-08-31	Genentech, Inc.	Compuestos heterocíclicos y métodos de uso
JO2885B1 (en)	2008-12-22	2015-03-15	ايلي ليلي اند كومباني	Protein kinase inhibitors
CA2748276A1 (en)	2008-12-30	2010-07-08	Arqule, Inc.	Substituted pyrazolo [3, 4-b] pyridine compounds
WO2010078421A1 (en)	2008-12-30	2010-07-08	Arqule, Inc.	Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
CA2748181C (en)	2009-01-06	2019-07-16	Nathanael S. Gray	Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
JOP20190231A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010083145A1 (en)	2009-01-16	2010-07-22	Merck Sharp & Dohme Corp.	IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS
DE102009007038A1 (de)	2009-02-02	2010-08-05	Merck Patent Gmbh	Metallkomplexe
JP2010180147A (ja)	2009-02-04	2010-08-19	Mitsubishi Gas Chemical Co Inc	シアン酸エステル化合物、およびその硬化物
JP5844159B2 (ja)	2009-02-09	2016-01-13	ユニヴェルシテデクス−マルセイユＵｎｉｖｅｒｓｉｔｅＤ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ	Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
TW201038569A (en)	2009-02-16	2010-11-01	Abbott Gmbh & Co Kg	Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en)	2009-03-04	2010-10-01	Gruenethal Gmbh	Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
US20100278835A1 (en)	2009-03-10	2010-11-04	Astrazeneca Uk Limited	Novel compounds 660
WO2010104047A1 (ja)	2009-03-11	2010-09-16	国立大学法人京都大学	多環芳香族化合物
JP2012520887A (ja)	2009-03-18	2012-09-10	シェーリングコーポレイション	ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
CN102438660A (zh)	2009-03-23	2012-05-02	美国西门子医疗解决公司	用于检测神经障碍的显像剂
ES2540119T3 (es)	2009-03-27	2015-07-08	Abbvie Inc.	Compuestos como ligandos de receptores cannabinoides
WO2010117425A1 (en)	2009-03-31	2010-10-14	Biogen Idec Ma Inc.	Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
ES2465971T3 (es)	2009-04-06	2014-06-09	University Health Network	Inhibidores de quinasa y método para tratar cáncer con los mismos
TW201040166A (en)	2009-04-07	2010-11-16	Astrazeneca Ab	Isoxazol-3(2H)-one analogs as therapeutic agents
GB0906472D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
GB0906470D0 (en)	2009-04-15	2009-05-20	Astex Therapeutics Ltd	New compounds
JP5531446B2 (ja)	2009-04-20	2014-06-25	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置および照明装置
ES2347630B1 (es)	2009-04-29	2011-09-08	Universitat Ramon Llull	Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
WO2010126960A1 (en)	2009-04-29	2010-11-04	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
US20100280067A1 (en)	2009-04-30	2010-11-04	Pakala Kumara Savithru Sarma	Inhibitors of acetyl-coa carboxylase
JO2860B1 (en)	2009-05-07	2015-03-15	ايلي ليلي اند كومباني	Phenylendazolyl compounds
JP5600891B2 (ja)	2009-05-15	2014-10-08	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置および照明装置
JP5604808B2 (ja)	2009-05-20	2014-10-15	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5629980B2 (ja)	2009-05-22	2014-11-26	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5568889B2 (ja)	2009-05-22	2014-08-13	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置、照明装置及び有機エレクトロルミネッセンス素子材料
JP5499519B2 (ja)	2009-05-27	2014-05-21	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置及び照明装置
WO2010136031A1 (en)	2009-05-27	2010-12-02	Københavns Universitet	Fibroblast growth factor receptor-derived peptides binding to ncam
GB0910003D0 (en)	2009-06-11	2009-07-22	Univ Leuven Kath	Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (ja)	2009-06-24	2014-10-08	コニカミノルタ株式会社	白色有機エレクトロルミネッセンス素子、表示装置及び照明装置
SMT201700430T1 (it)	2009-06-25	2018-01-11	Alkermes Pharma Ireland Ltd	Composti eterociclici per il trattamento di disturbi neurologici e psicologici
US8883888B2 (en)	2009-06-30	2014-11-11	Zeon Corporation	Diarylamine compounds, aging inhibitor, polymer composition, crosslinked rubber product and molded article of the crosslinked product, and method of producing diarylamine compound
US20120135997A1 (en)	2009-07-17	2012-05-31	Shionogi & Co., Ltd.	Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
US8680077B2 (en)	2009-07-24	2014-03-25	Duke University	Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (fr)	2009-07-30	2012-08-24	Sanofi Aventis	Formulation pharmaceutique
TWI468402B (zh)	2009-07-31	2015-01-11	必治妥美雅史谷比公司	降低β－類澱粉生成之化合物
IN2012DN01254A (it)	2009-08-05	2015-05-15	Versitech Ltd
JP2012197231A (ja)	2009-08-06	2012-10-18	Oncotherapy Science Ltd	Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
HUE028584T2 (en)	2009-08-07	2016-12-28	Chugai Pharmaceutical Co Ltd	Aminopyrazole derivatives
WO2011018894A1 (en)	2009-08-10	2011-02-17	Raqualia Pharma Inc.	Pyrrolopyrimidine derivatives as potassium channel modulators
CN102573846B (zh)	2009-08-17	2015-10-07	因特利凯公司	杂环化合物及其用途
JP5577650B2 (ja)	2009-08-24	2014-08-27	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、有機エレクトロルミネッセンス素子材料、表示装置及び照明装置
KR101184115B1 (ko)	2009-08-31	2012-09-18	일동제약주식회사	신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
CN102656163B (zh)	2009-09-03	2016-01-13	拜奥埃内杰尼克斯公司	抑制pask的杂环化合物
US9340528B2 (en)	2009-09-04	2016-05-17	Bayer Pharma Aktiengesellschaft	Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en)	2009-09-09	2011-03-17	Achaogen, Inc.	Antibacterial fluoroquinolone analogs
US9481675B2 (en)	2009-09-11	2016-11-01	Merck Sharp & Dohme Corp.	Gyrase inhibitors
WO2011035376A1 (en)	2009-09-24	2011-03-31	Romar Engineering Pty Ltd	A mould or mould core and a method of manufacturing a mould or mould core
EP2483275B1 (en)	2009-10-01	2014-10-15	Merck Sharp & Dohme Corp.	HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8466155B2 (en)	2009-10-02	2013-06-18	Boehringer Ingelheim International Gmbh	Pyrimidines
GB0917571D0 (en)	2009-10-07	2009-11-25	Karobio Ab	Novel estrogen receptor ligands
EP2308866A1 (de)	2009-10-09	2011-04-13	Bayer CropScience AG	Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
FR2951172B1 (fr)	2009-10-13	2014-09-26	Pf Medicament	Derives pyrazolopyridines en tant qu'agent anticancereux
US20120232062A1 (en)	2009-10-20	2012-09-13	Eiger Biopharmaceuticals, Inc.	Azaindazoles to treat flaviviridae virus infection
KR20110043270A (ko)	2009-10-21	2011-04-27	(주)씨에스엘쏠라	유기발광화합물 및 이를 구비한 유기발광소자
NZ598933A (en)	2009-10-22	2013-04-26	Gilead Sciences Inc	Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011050245A1 (en)	2009-10-23	2011-04-28	Yangbo Feng	Bicyclic heteroaryls as kinase inhibitors
SG10201500511TA (en)	2009-10-26	2015-03-30	Signal Pharm Llc	Methods Of Synthesis And Purification Of Heteroaryl Compounds
ES2524548T3 (es)	2009-10-30	2014-12-10	Novartis Ag	N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
KR20110049217A (ko)	2009-11-04	2011-05-12	다우어드밴스드디스플레이머티리얼 유한회사	신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
GB0919432D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use
EA201290210A1 (ru)	2009-11-06	2012-10-30	Плексксикон, Инк.	Соединения и способы модуляции киназы и показания для их применения
NZ599041A (en)	2009-11-13	2014-05-30	Genosco	Kinase inhibitors
JP2013511541A (ja)	2009-11-18	2013-04-04	プレキシコンインコーポレーテッド	キナーゼ調節のための化合物および方法、ならびにその適応
JP2013032290A (ja)	2009-11-20	2013-02-14	Dainippon Sumitomo Pharma Co Ltd	新規縮合ピリミジン誘導体
WO2011062885A1 (en)	2009-11-23	2011-05-26	Schering Corporation	Fused bicyclic pyrimidine derivatives and methods of use thereof
JP2013512251A (ja)	2009-11-24	2013-04-11	アンプリミューン、インコーポレーテッド	Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2332939A1 (en)	2009-11-26	2011-06-15	Æterna Zentaris GmbH	Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
US8785639B2 (en)	2009-12-01	2014-07-22	Abbvie Inc.	Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
JP2011116840A (ja)	2009-12-02	2011-06-16	Fujifilm Corp	顔料微粒子分散体、これを用いた光硬化性組成物及びカラーフィルタ
AR079257A1 (es)	2009-12-07	2012-01-04	Novartis Ag	Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
MX2012007154A (es)	2009-12-17	2012-08-01	Merck Sharp & Dohme	Aminopirimidinas como inhibidores de syk.
JP2013514986A (ja)	2009-12-18	2013-05-02	ノバルティスアーゲー	血液癌の処置方法
CA2785499C (en)	2009-12-22	2017-05-02	Vertex Pharmaceuticals Incorporated	Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2011079231A1 (en)	2009-12-23	2011-06-30	Gatekeeper Pharmaceutical, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
FR2954317B1 (fr)	2009-12-23	2012-01-27	Galderma Res & Dev	Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954315B1 (fr)	2009-12-23	2012-02-24	Galderma Res & Dev	Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
EP2519241A2 (en)	2009-12-28	2012-11-07	Afraxis, Inc.	Methods for treating autism
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
JP2013515785A (ja)	2009-12-29	2013-05-09	ポリエラコーポレイション	有機半導体としてのチオン酸化芳香族ビスイミドおよびそれを組み込む装置
WO2011080755A1 (en)	2009-12-29	2011-07-07	Advinus Therapeutics Private Limited	Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011082266A2 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted heterocyclic compounds
US8329705B2 (en)	2009-12-30	2012-12-11	Arqule, Inc.	Substituted triazolo-pyrazine compounds
WO2011082273A2 (en)	2009-12-30	2011-07-07	Arqule, Inc.	Substituted pyrrolo-aminopyrimidine compounds
CN102115026A (zh)	2009-12-31	2011-07-06	清华大学	一维纳米结构、其制备方法及一维纳米结构作标记的方法
US20130022629A1 (en)	2010-01-04	2013-01-24	Sharpe Arlene H	Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
AR079975A1 (es)	2010-01-06	2012-03-07	British Columbia Cancer Agency	Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
KR101483215B1 (ko)	2010-01-29	2015-01-16	한미약품 주식회사	단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011097717A1 (en)	2010-02-15	2011-08-18	University Of Victoria Innovation And Development Corporation	Synthesis of bicyclic compounds and method for their use as therapeutic agents
WO2011103196A1 (en)	2010-02-17	2011-08-25	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SA111320200B1 (ar)	2010-02-17	2014-02-16	ديبيوفارم اس ايه	مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
DE112011100604T5 (de)	2010-02-18	2013-01-31	Ntn Corporation	Verdicker, Schmierfett, Verfahren zur Herstellung derselben und fettgeschmiertes Lager
WO2011103460A1 (en)	2010-02-18	2011-08-25	Medivation Technologies, Inc.	Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
EP2536410B1 (en)	2010-02-18	2015-09-23	Merck Sharp & Dohme Corp.	Substituted pyrimidine derivatives and their use in treating viral infections
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011103557A1 (en)	2010-02-22	2011-08-25	Advanced Cancer Therapeutics, Llc	Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
WO2011105161A1 (ja)	2010-02-26	2011-09-01	新日鐵化学株式会社	有機電界発光素子
US20130045203A1 (en)	2010-03-02	2013-02-21	Emory University	Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
WO2011111880A1 (ko)	2010-03-08	2011-09-15	주식회사 메디젠텍	세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
US20110237599A1 (en)	2010-03-10	2011-09-29	Kalypsys, Inc.	Heterocyclic inhibitors of histamine receptors for the treatment of disease
PT2545052E (pt)	2010-03-11	2015-02-18	Gilead Connecticut Inc	Inibidores da syk à base de imidazopiridinas
KR20130006664A (ko)	2010-03-16	2013-01-17	다나-파버 캔서 인스티튜트 인크.	인다졸 화합물 및 그의 용도
CN102884060B (zh)	2010-03-24	2019-07-19	阿米泰克治疗方案公司	用于抑制激酶的杂环化合物
EP2552922A1 (en)	2010-03-31	2013-02-06	Bristol-Myers Squibb Company	Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (zh)	2010-04-02	2012-04-25	济南海乐医药技术开发有限公司	基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
JP5724204B2 (ja)	2010-04-07	2015-05-27	コニカミノルタ株式会社	有機エレクトロルミネッセンス素子、表示装置、及び照明装置
EP2558474B1 (en)	2010-04-13	2015-11-25	Rigel Pharmaceuticals, Inc.	2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
MX2012012051A (es)	2010-04-16	2012-11-22	Novartis Ag	Compuesto organico para usarse en el tratamiento de cancer de higado.
JP2013525370A (ja)	2010-04-22	2013-06-20	ヤンセンファーマシューティカエヌ．ベー．	ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
CA2812043A1 (en)	2010-04-23	2011-10-27	Kineta, Inc.	Pyrimidinedione anti-viral compounds
US8481555B2 (en)	2010-04-30	2013-07-09	Bristol-Myers Squibb Company	Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
US8759398B2 (en)	2010-05-03	2014-06-24	Biolink Life Sciences, Inc.	Phosphorus binder composition for treatment of hyperphosphatemia
WO2011140338A1 (en)	2010-05-05	2011-11-10	Gatekeeper Pharmaceuticals, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
CA2800311A1 (en)	2010-05-11	2011-11-17	Aveo Pharmaceuticals, Inc.	Anti-fgfr2 antibodies
TWI513694B (zh)	2010-05-11	2015-12-21	Amgen Inc	抑制間變性淋巴瘤激酶的嘧啶化合物
WO2011141848A1 (en)	2010-05-11	2011-11-17	Pfizer Inc.	Morpholine compounds as mineralocorticoid receptor antagonists
CA2799154A1 (en)	2010-05-12	2011-11-17	Abbvie Inc.	Indazole inhibitors of kinase
EP3848040A1 (en)	2010-05-12	2021-07-14	Spectrum Pharmaceuticals, Inc.	Lanthanum dioxycarbonate and use
GB201008134D0 (en)	2010-05-14	2010-06-30	Medical Res Council Technology	Compounds
WO2011147199A1 (en)	2010-05-28	2011-12-01	Versitech Limited	Compounds and methods for treating viral infections
WO2011147198A1 (en)	2010-05-28	2011-12-01	Versitech Limited	Compounds and methods for treatment of proliferative diseases
WO2011153553A2 (en)	2010-06-04	2011-12-08	The Regents Of The University Of California	Methods and compositions for kinase inhibition
PT2576541T (pt)	2010-06-04	2016-07-08	Hoffmann La Roche	Derivados de aminopirimidina como moduladores de lrrk2
WO2011155983A1 (en)	2010-06-07	2011-12-15	Bikam Pharmaceuticals Inc.	Opsin-binding ligands, compositions and methods of use
TW201210597A (en)	2010-06-09	2012-03-16	Gilead Sciences Inc	Inhibitors of hepatitis C virus
US8299117B2 (en)	2010-06-16	2012-10-30	Metabolex Inc.	GPR120 receptor agonists and uses thereof
JP2013532153A (ja)	2010-06-18	2013-08-15	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8999957B2 (en)	2010-06-24	2015-04-07	Merck Sharp & Dohme Corp.	Heterocyclic compounds as ERK inhibitors
US8907053B2 (en)	2010-06-25	2014-12-09	Aurigene Discovery Technologies Limited	Immunosuppression modulating compounds
KR101486782B1 (ko)	2010-06-27	2015-01-28	킹 사우드 유니버시티	무한 중첩된 해시 체인들에 의한 1회용 패스워드 인증
CA2803446C (en)	2010-07-02	2019-06-04	University Health Network	Use of plk4 antagonists for treating pten mutant diseases
FR2962437B1 (fr)	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
CN103080106A (zh)	2010-07-06	2013-05-01	诺瓦提斯公司	用作激酶抑制剂的环醚化合物
FR2962438B1 (fr)	2010-07-06	2012-08-17	Sanofi Aventis	Derives d'indolizines, procedes de preparation et application en therapeutique
DE102010031127A1 (de)	2010-07-08	2012-01-12	Endress + Hauser Flowtec Ag	Messaufnehmer eines thermischen Durchflussmessgeräts zur Ermittlung des Durchflusses eines Mediums durch ein Messrohr und Verfahren zu dessen Herstellung
US8962830B2 (en)	2010-07-09	2015-02-24	The Walter And Eliza Hall Institute Of Medical Research	Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en)	2010-07-13	2012-01-19	Edward Roberts	Peptidomimetic galanin receptor modulators
EP2595996A2 (en)	2010-07-14	2013-05-29	Merck Sharp & Dohme Corp.	Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors
TW201206946A (en)	2010-07-15	2012-02-16	Bristol Myers Squibb Co	Compounds for the reduction of beta-amyloid production
WO2012008564A1 (ja)	2010-07-16	2012-01-19	協和発酵キリン株式会社	含窒素芳香族複素環誘導体
WO2012008563A1 (ja)	2010-07-16	2012-01-19	協和発酵キリン株式会社	含窒素芳香族複素環誘導体
EP2598505B1 (en)	2010-07-28	2015-03-18	Bayer Intellectual Property GmbH	Substituted imidazo[1,2-b]pyridazines
EP2413140A1 (en)	2010-07-29	2012-02-01	Sanofi	Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
EP2806008A1 (en)	2010-07-30	2014-11-26	Rohm And Haas Electronic Materials Korea Ltd.	Organic electroluminescent device employing organic light emitting compound as light emitting material
WO2012019093A1 (en)	2010-08-05	2012-02-09	Human Biomolecular Research Institute	Synthetic compounds and methods to decrease nicotine self-administration
US9051280B2 (en)	2010-08-13	2015-06-09	AbbVie Deutschland GmbH & Co. KG	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en)	2010-08-13	2014-11-11	Abbott Laboratories	Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012027239A1 (en)	2010-08-23	2012-03-01	Schering Corporation	NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
BR112013007499A2 (pt)	2010-09-01	2016-07-12	Genentech Inc	piridazinonas - métodos de criação e usos
CA2809836C (en)	2010-09-01	2019-01-15	Gilead Connecticut, Inc.	Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
WO2012032065A1 (en)	2010-09-08	2012-03-15	Glaxo Group Limited	Indazole derivatives for use in the treatment of influenza virus infection
RS54286B1 (en)	2010-09-08	2016-02-29	Glaxosmithkline Intellectual Property Development Limited	POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
AR082799A1 (es)	2010-09-08	2013-01-09	Ucb Pharma Sa	Derivados de quinolina y quinoxalina como inhibidores de quinasa
TWI541243B (zh)	2010-09-10	2016-07-11	拜耳知識產權公司	經取代咪唑并嗒
WO2012035996A1 (ja)	2010-09-14	2012-03-22	保土谷化学工業株式会社	電荷制御剤及びそれを用いたトナー
CN102399220A (zh)	2010-09-15	2012-04-04	黄振华	三并环类PI3K和mTOR双重抑制剂
CN102399233B (zh)	2010-09-15	2014-08-13	山东轩竹医药科技有限公司	PI3K和mTOR双重抑制剂类化合物
WO2012036233A1 (ja)	2010-09-17	2012-03-22	塩野義製薬株式会社	メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
GB201015949D0 (en)	2010-09-22	2010-11-03	Medical Res Council Technology	Compounds
JO3062B1 (ar)	2010-10-05	2017-03-15	Lilly Co Eli	R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
WO2012054364A2 (en)	2010-10-22	2012-04-26	Merck Sharp & Dohme Corp.	Bicyclic diamines as janus kinase inhibitors
CN106967074A (zh)	2010-10-25	2017-07-21	G1治疗公司	Cdk抑制剂
JP2012092049A (ja)	2010-10-27	2012-05-17	Sumitomo Chemical Co Ltd	有害動物防除組成物及び有害動物の防除方法
WO2012058211A2 (en)	2010-10-29	2012-05-03	Emory University	Quinazoline derivatives, compositions, and uses related thereto
WO2012061337A1 (en)	2010-11-02	2012-05-10	Exelixis, Inc.	Fgfr2 modulators
WO2012062462A1 (en)	2010-11-10	2012-05-18	Grünenthal GmbH	Substituted heteroaromatic carboxamide and urea derivatives as vanilloid receptor ligands
CN103201261A (zh)	2010-11-10	2013-07-10	埃科特莱茵药品有限公司	用作为食欲素受体拮抗剂的内酰胺衍生物
JP2012116825A (ja)	2010-11-11	2012-06-21	Ehime Univ	アセンジイミド化合物の製造方法
KR101171232B1 (ko)	2010-11-15	2012-08-06	단국대학교 산학협력단	스파이로 화합물 및 이를 포함하는 유기전계 발광소자
WO2012065297A1 (en)	2010-11-16	2012-05-24	Impact Therapeutics, Inc.	3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
AU2011329806A1 (en)	2010-11-17	2013-05-30	Amgen Inc.	Quinoline derivatives as PIK3 inhibitors
CA2818389A1 (en)	2010-11-18	2012-05-24	Kasina Laila Innova Pharmaceuticals Private Limited	Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
WO2012078777A1 (en)	2010-12-09	2012-06-14	Amgen Inc.	Bicyclic compounds as pim inhibitors
EP2651405A2 (en)	2010-12-14	2013-10-23	Electrophoretics Limited	Casein kinase 1 (ck1 ) inhibitors
US9073892B2 (en)	2010-12-20	2015-07-07	Merck Serono S.A.	Indazolyl triazol derivatives
AU2011348637B2 (en)	2010-12-22	2015-08-20	Leo Laboratories Limited	Ingenol-3-acylates III and ingenol-3-carbamates
EP2655312A1 (en)	2010-12-22	2013-10-30	Leo Laboratories Limited	3-acyl-ingenols ii
EP2468258A1 (en)	2010-12-22	2012-06-27	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2011349669A1 (en)	2010-12-23	2013-07-11	Amgen Inc.	Heterocyclic compounds and their uses
JP5691508B2 (ja)	2010-12-27	2015-04-01	Jnc株式会社	ジイミド化合物ならびにインクジェット用インクおよびその用途
KR101466150B1 (ko)	2010-12-31	2014-11-27	제일모직 주식회사	유기광전소자용 화합물 및 이를 포함하는 유기광전소자
JP5860818B2 (ja)	2011-01-06	2016-02-16	Ｊｘ日鉱日石エネルギー株式会社	イミド化合物及びその製造方法、グリース用増ちょう剤並びにグリース組成物
US8362023B2 (en)	2011-01-19	2013-01-29	Hoffmann-La Roche Inc.	Pyrazolo pyrimidines
FR2970967B1 (fr)	2011-01-27	2013-02-15	Pf Medicament	Derives de type azaindazole ou diazaindazole comme medicament
EP2487159A1 (en)	2011-02-11	2012-08-15	MSD Oss B.V.	RorgammaT inhibitors
WO2012112961A1 (en)	2011-02-18	2012-08-23	Medivation Technologies, Inc.	Compounds and methods of treating hypertension
EP2678016B1 (en)	2011-02-23	2016-08-10	Intellikine, LLC	Heterocyclic compounds and uses thereof
TWI532742B (zh)	2011-02-28	2016-05-11	艾伯維有限公司	激酶之三環抑制劑
AU2012229107A1 (en)	2011-03-17	2013-09-19	Novartis Ag	FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
CA2830516C (en)	2011-03-23	2017-01-24	Amgen Inc.	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ITPD20110091A1 (it)	2011-03-24	2012-09-25	Univ Padova	Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
AR085530A1 (es)	2011-03-25	2013-10-09	Abbott Lab	Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
BR112013024717A2 (pt)	2011-04-07	2017-08-08	Genentech Inc	anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
FR2974088A1 (fr)	2011-04-12	2012-10-19	Pf Medicament	Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
JP5836481B2 (ja)	2011-05-16	2015-12-24	ジェネンテック，インコーポレイテッド	Ｆｇｆｒ１アゴニスト及び使用方法
US20140288069A1 (en)	2011-05-17	2014-09-25	Bayer Intellectual Property Gmbh	Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
US9376438B2 (en)	2011-05-17	2016-06-28	Principia Biopharma, Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012255148A1 (en)	2011-05-19	2013-11-07	Novartis Ag	4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1H - benzimidazol - 2 - yl] - 1H - quinolin-2-one for use in the treatment of adenoid cystic carcinoma
EP2714692B1 (en)	2011-06-01	2017-03-22	Bayer Intellectual Property GmbH	Substituted aminoimidazopyridazines
TW201316991A (zh)	2011-06-03	2013-05-01	Millennium Pharm Inc	Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
US9543524B2 (en)	2011-06-13	2017-01-10	Lg Chem, Ltd.	Compounds and organic electronic device using same
JP5944497B2 (ja)	2011-06-22	2016-07-05	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	ヘテロシクリルアミノイミダゾピリダジン
US8846656B2 (en)	2011-07-22	2014-09-30	Novartis Ag	Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
TWI601727B (zh)	2011-08-12	2017-10-11	日產化學工業股份有限公司	三環雜環化合物及ｊａｋ（傑納斯激酶）抑制劑
BR112014003296A2 (pt)	2011-08-12	2017-03-14	Hoffmann La Roche	composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto
JP2013049251A (ja)	2011-08-31	2013-03-14	Fujifilm Corp	レーザー彫刻用レリーフ印刷版原版、並びに、レリーフ印刷版及びその製版方法
WO2013033981A1 (zh)	2011-09-06	2013-03-14	江苏先声药物研究有限公司	一类2,7-萘啶衍生物及其制备方法和应用
US9345705B2 (en)	2011-09-15	2016-05-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
US9376435B2 (en)	2011-09-23	2016-06-28	Jawaharlal Nehru Centre For Advanced Scientific Research	Chromophores for the detection of volatile organic compounds
CN103814029B (zh)	2011-09-23	2016-10-12	拜耳知识产权有限责任公司	取代的咪唑并哒嗪
WO2013049352A2 (en)	2011-09-30	2013-04-04	Kineta, Inc.	Anti-viral compounds
UA111382C2 (uk)	2011-10-10	2016-04-25	Оріон Корпорейшн	Інгібітори протеїнкінази
US9580390B2 (en)	2011-10-12	2017-02-28	University Health Network	Indazole compounds as kinase inhibitors and method of treating cancer with same
KR101897044B1 (ko)	2011-10-20	2018-10-23	에스에프씨 주식회사	유기금속 화합물 및 이를 포함하는 유기전계발광소자
CN103889422A (zh)	2011-10-28	2014-06-25	诺华股份有限公司	治疗胃肠道间质瘤的方法
WO2013063003A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Method of treating gastrointestinal stromal tumors
WO2013088191A1 (en)	2011-12-12	2013-06-20	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
CN103998590B (zh)	2011-12-13	2019-02-01	艺康美国股份有限公司	浓的器皿洗涤组合物和方法
FR2985258A1 (fr)	2011-12-28	2013-07-05	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
FR2985257B1 (fr)	2011-12-28	2014-02-14	Sanofi Sa	Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
US10026905B2 (en)	2012-01-18	2018-07-17	Duk San Neolux Co., Ltd.	Compound, organic electric element using the same, and an electronic device thereof
WO2013109027A1 (ko)	2012-01-18	2013-07-25	덕산하이메탈(주)	화합물, 이를 이용한 유기전기소자 및 그 전자 장치
ES2516392T3 (es)	2012-01-19	2014-10-30	Taiho Pharmaceutical Co., Ltd.	Compuesto de alquinilbenceno 3,5-disustituido y sal del mismo
WO2013124316A1 (en)	2012-02-23	2013-08-29	Bayer Intellectual Property Gmbh	Substituted benzothienyl-pyrrolotriazines and uses thereof
JP2013179181A (ja)	2012-02-28	2013-09-09	Sumitomo Chemical Co Ltd	有機光電変換素子
MA37405A1 (fr)	2012-03-14	2016-03-31	Lupin Ltd	Composés hétérocyclyle
RU2643326C2 (ru)	2012-03-30	2018-01-31	Новартис Аг	Ингибитор рецептора фрф для применения в лечении гипофосфатемических заболеваний
JP5120580B1 (ja)	2012-05-14	2013-01-16	Ｊｓｒ株式会社	液晶配向剤
WO2013175468A2 (en)	2012-05-20	2013-11-28	Tel Hashomer Medical Research Infrastructure And Services Ltd.	Prosthetic mitral valve
SMT202000673T1 (it)	2012-06-13	2021-01-05	Incyte Holdings Corp	Composti triciclici sostituiti come inibitori di fgfr
RU2015104537A (ru)	2012-07-11	2016-08-27	Новартис Аг	Способы лечения стромальных опухолей желудочно-кишечного тракта
LT2872491T (lt)	2012-07-11	2021-08-25	Blueprint Medicines Corporation	Fibroblasto augimo faktoriaus receptoriaus inhibitoriai
WO2014019186A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
KR101985259B1 (ko)	2012-08-10	2019-06-03	제이에스알 가부시끼가이샤	액정 배향제 및 화합물
WO2014044846A1 (en)	2012-09-24	2014-03-27	Evotec (Uk) Ltd.	3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en)	2012-09-26	2014-04-03	Evotec (Uk) Ltd.	Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en)	2012-10-15	2014-04-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
KR102000211B1 (ko)	2012-10-29	2019-09-30	삼성디스플레이 주식회사	유기금속 화합물 및 이를 포함한 유기 발광 소자
US20140148548A1 (en)	2012-11-28	2014-05-29	Central Glass Company, Limited	Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
AU2013352568B2 (en)	2012-11-28	2019-09-19	Merck Sharp & Dohme Llc	Compositions and methods for treating cancer
CN104968664A (zh)	2012-12-12	2015-10-07	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的并环化合物
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
TWI629266B (zh)	2012-12-28	2018-07-11	藍印藥品公司	纖維母細胞生長因子受體之抑制劑
WO2014105849A1 (en)	2012-12-28	2014-07-03	Xoma (Us) Llc	Antibodies specific for fgfr4 and methods of use
KR102030587B1 (ko)	2013-01-09	2019-10-10	에스에프씨주식회사	두 개의 나프틸기를 포함하는 비대칭 안트라센 유도체 및 이를 포함하는 유기 발광 소자
CN103588771B (zh)	2013-01-15	2016-01-27	苏州云轩医药科技有限公司	具有刺猬通路拮抗剂活性的嘧啶类抗肿瘤化合物
WO2014113191A1 (en)	2013-01-15	2014-07-24	Xiaohu Zhang	Hedgehog pathway signaling inhibitors and therapeutic applications thereof
KR101456626B1 (ko)	2013-02-01	2014-11-03	대영이앤비 주식회사	냉장고 부압 방지 장치
JP6311093B2 (ja)	2013-03-07	2018-04-18	国立大学法人九州大学	超分子複合体、発光体、および有機化合物検出用のセンサー素子
WO2014138485A1 (en)	2013-03-08	2014-09-12	Irm Llc	Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US20140371238A1 (en)	2013-03-13	2014-12-18	Flatley Discovery Lab	Compounds and methods for the treatment of cystic fibrosis
US9498532B2 (en)	2013-03-13	2016-11-22	Novartis Ag	Antibody drug conjugates
EP2970258B1 (en)	2013-03-14	2018-04-18	AbbVie Deutschland GmbH & Co KG	Novel inhibitor compounds of phosphodiesterase type 10a
BR112015022191A8 (pt)	2013-03-15	2018-01-23	Celgene Avilomics Res Inc	compostos heteroarila e usos dos mesmos
CA2907243C (en)	2013-03-15	2021-12-28	Celgene Avilomics Research, Inc.	Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
AR095464A1 (es)	2013-03-15	2015-10-21	Celgene Avilomics Res Inc	Compuestos de heteroarilo y usos de los mismos
US9499522B2 (en)	2013-03-15	2016-11-22	Blueprint Medicines Corporation	Compositions useful for treating disorders related to kit
TWI628176B (zh)	2013-04-04	2018-07-01	奧利安公司	蛋白質激酶抑制劑
KR101573611B1 (ko)	2013-04-17	2015-12-01	주식회사 엘지화학	플러렌 유도체, 이를 이용한 유기 태양 전지 및 이의 제조 방법
WO2014170063A1 (en)	2013-04-19	2014-10-23	Covagen Ag	Novel bispecific binding molecules with antitumoral activity
SG11201508328PA (en)	2013-04-19	2015-11-27	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
GB201307577D0 (en)	2013-04-26	2013-06-12	Astex Therapeutics Ltd	New compounds
WO2014182829A1 (en)	2013-05-09	2014-11-13	Principia Biopharma Inc.	Quinolone derivatives as fibroblast growth factor inhibitors
KR20160021134A (ko)	2013-06-14	2016-02-24	사노피	방광암 치료용 피라졸로피리딘 유도체
EP3013797B1 (en)	2013-06-28	2018-01-03	BeiGene, Ltd.	Fused tricyclic amide compounds as multiple kinase inhibitors
BR112015032539B1 (pt)	2013-06-28	2022-07-12	Beigene, Ltd	Compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase e composição farmacêutica compreendendo os referidos compostos
MX2015017821A (es)	2013-07-02	2016-04-15	Syngenta Participations Ag	Heterociclos bi-o triciclicos activos como plaguicidas con sustituyentes que contienen azufre.
US9783504B2 (en)	2013-07-09	2017-10-10	Dana-Farber Cancer Institute, Inc.	Kinase inhibitors for the treatment of disease
JP6018547B2 (ja)	2013-07-09	2016-11-02	大成ロテック株式会社	舗装機械
DK3019496T3 (da)	2013-07-11	2019-12-09	Acea Therapeutics Inc	Pyrimidinderivater som kinaseinhibitorer
TW201605452A (zh)	2013-08-28	2016-02-16	安斯泰來製藥股份有限公司	以嘧啶化合物作爲有效成分之醫藥組成物
LT3057943T (lt)	2013-10-18	2018-11-12	Eisai R&D Management Co., Ltd.	Pirimidino fgfr4 slopikliai
CN105683188B (zh)	2013-10-25	2018-02-09	诺华股份有限公司	作为fgfr4抑制剂的稠环二环吡啶基衍生物
PT3395814T (pt)	2013-10-25	2022-07-27	Blueprint Medicines Corp	Inibidores do recetor do fator de crescimento de fibroblastos
FR3012330B1 (fr)	2013-10-29	2015-10-23	Oreal	Composition biphase comprenant un ester d'acide gras et de sucre ou un alkylpolyglucoside liquide, de hlb < 8, et un alcane ramifie en c8-c18
WO2015066452A2 (en)	2013-11-01	2015-05-07	Foundation Medicine, Inc.	Methods of treating pediatric cancers
US9695165B2 (en)	2014-01-15	2017-07-04	Blueprint Medicines Corporation	Inhibitors of the fibroblast growth factor receptor
PE20170774A1 (es)	2014-08-19	2017-07-04	Shanghai Haihe Pharmaceutical Co Ltd	Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos
CN104262330B (zh)	2014-08-27	2016-09-14	广东东阳光药业有限公司	一种脲取代联苯类化合物及其组合物及用途
US10350206B2 (en)	2014-09-19	2019-07-16	Bayer Pharma Aktiengesellschaft	Benzyl substituted indazoles as BUB1 inhibitors
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016064960A1 (en)	2014-10-22	2016-04-28	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
JP2018510849A (ja)	2015-02-20	2018-04-19	オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ	ソベチロムの誘導体
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
UA121669C2 (uk)	2015-02-20	2020-07-10	Інсайт Корпорейшн	Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR20180014778A (ko)	2015-06-03	2018-02-09	트리아스텍 인코포레이티드	제형 및 이의 용도
SG10201912066SA (en)	2015-07-15	2020-02-27	Protagonist Therapeutics Inc	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6717927B2 (ja)	2015-07-15	2020-07-08	キャボットコーポレイションＣａｂｏｔＣｏｒｐｏｒａｔｉｏｎ	シリカで補強されたエラストマー複合材の製造方法およびそれを含む製品
LT3322701T (lt)	2015-07-15	2019-07-10	F. Hoffmann-La Roche Ag	Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
GB201512369D0 (en)	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
PL3328419T3 (pl)	2015-07-30	2021-12-27	Macrogenics, Inc.	Cząsteczki wiążące pd-1 i sposoby ich zastosowania
WO2017023989A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024015A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en)	2015-08-03	2019-02-19	Samumed, Llc	3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10231956B2 (en)	2015-08-03	2019-03-19	Samumed, Llc	3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10188634B2 (en)	2015-08-03	2019-01-29	Samumed, Llc	3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024025A1 (en)	2015-08-03	2017-02-09	Sunil Kumar Kc	3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023972A1 (en)	2015-08-03	2017-02-09	Samumed, Llc.	3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
CA2996018C (en)	2015-08-20	2024-02-06	Changzhou Jiekai Pharmatech Co., Ltd.	Pyrazolo fused heterocyclic compounds as erk inhibitors
EP3356349A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
TW201718581A (zh)	2015-10-19	2017-06-01	英塞特公司	作為免疫調節劑之雜環化合物
WO2017070708A1 (en)	2015-10-23	2017-04-27	Array Biopharma, Inc.	2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
DK3377488T3 (da)	2015-11-19	2022-10-03	Incyte Corp	Heterocykliske forbindelser som immunomodulatorer
TW201726623A (zh)	2015-12-17	2017-08-01	英塞特公司	作為免疫調節劑之雜環化合物
ES2844374T3 (es)	2015-12-22	2021-07-22	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
TW201808950A (zh)	2016-05-06	2018-03-16	英塞特公司	作為免疫調節劑之雜環化合物
ES2905980T3 (es)	2016-05-26	2022-04-12	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
PE20190731A1 (es)	2016-06-20	2019-05-23	Incyte Corp	Compuestos heterociclicos como inmunomoduladores
US10138248B2 (en)	2016-06-24	2018-11-27	Incyte Corporation	Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
ES2930092T3 (es)	2016-07-14	2022-12-07	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en)	2016-08-29	2018-03-01	Incyte Corporation	Heterocyclic compounds as immunomodulators
CN109641868B (zh)	2016-08-30	2021-12-03	广东东阳光药业有限公司	流感病毒复制抑制剂及其使用方法和用途
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019003938A (es)	2016-10-05	2019-06-10	Zeno Royalties & Milestones Llc	Compuestos espirociclicos.
KR101755556B1 (ko)	2016-11-18	2017-07-07	주식회사 케마스	육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko)	2016-11-21	2018-03-05	주식회사 케마스	육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko)	2016-12-05	2018-03-30	주식회사 케마스	육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko)	2016-12-09	2018-05-14	주식회사 케마스	육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
EP3558963B1 (en)	2016-12-22	2022-03-23	Incyte Corporation	Bicyclic heteroaromatic compounds as immunomodulators
ES2874756T3 (es)	2016-12-22	2021-11-05	Incyte Corp	Derivados de triazolo[1,5-A]piridina como inmunomoduladores
MD3558990T2 (ro)	2016-12-22	2023-02-28	Incyte Corp	Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
IL295660A (en)	2016-12-22	2022-10-01	Incyte Corp	Benzooxazole derivatives as immunomodulators
US20180179179A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
WO2018119263A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds derivatives as pd-l1 internalization inducers
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018234354A1 (en)	2017-06-20	2018-12-27	Grünenthal GmbH	NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
CN111032656B (zh)	2017-08-22	2022-12-02	捷思英达医药技术（上海）有限公司	杂环化合物激酶抑制剂及其药物组合物和应用
CA3079607A1 (en)	2017-10-19	2019-04-25	Effector Therapeutics, Inc.	Benzimidazole-indole inhibitors of mnk1 and mnk2
PT3717471T (pt)	2017-12-02	2022-03-08	Galapagos Nv	Novos compostos e composições farmacêuticas dos mesmos para o tratamento de doenças
FI3774791T3 (fi)	2018-03-30	2023-03-21	Incyte Corp	Heterosyklisiä yhdisteitä immunomodulaattoreina
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
FI3788047T3 (fi)	2018-05-04	2024-11-02	Incyte Corp	Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
CN112752756B (zh)	2018-05-11	2024-06-25	因赛特公司	作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
KR20210075071A (ko)	2018-08-14	2021-06-22	오스테오큐씨 인코포레이티드	피롤로-디피리딘 화합물
DK3846904T3 (da)	2018-09-07	2023-08-21	Merck Patent Gmbh	5-morpholin-4-yl-pyrazolo[4,3-b]pyridinderivater
WO2020081898A1 (en)	2018-10-20	2020-04-23	The Johns Hopkins University	Non-invasive urinary biomarkers for the detection of urothelial carcinoma of the bladder
JP2022515197A (ja)	2018-12-19	2022-02-17	アレイバイオファーマインコーポレイテッド	がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
CN113490666A (zh)	2018-12-19	2021-10-08	奥瑞生物药品公司	作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar)	2019-10-14	2023-01-30	Incyte Corp	حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
PE20221504A1 (es)	2019-12-04	2022-09-30	Incyte Corp	Derivados de un inhibidor de fgfr
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (en)	2021-04-12	2024-02-21	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent

2013
- 2013-06-12 SM SM20200673T patent/SMT202000673T1/it unknown
- 2013-06-12 EP EP16203866.5A patent/EP3176170B1/en active Active
- 2013-06-12 SI SI201330583A patent/SI2861595T1/sl unknown
- 2013-06-12 PE PE2019000866A patent/PE20190736A1/es unknown
- 2013-06-12 SI SI201331805T patent/SI3495367T1/sl unknown
- 2013-06-12 NZ NZ730134A patent/NZ730134A/en unknown
- 2013-06-12 MY MYPI2014003396A patent/MY171375A/en unknown
- 2013-06-12 CN CN201710874686.0A patent/CN107652289B/zh active Active
- 2013-06-12 EP EP18198112.7A patent/EP3495367B1/en active Active
- 2013-06-12 ME MEP-2017-67A patent/ME02651B/me unknown
- 2013-06-12 SG SG11201408238WA patent/SG11201408238WA/en unknown
- 2013-06-12 SI SI201331298T patent/SI3176170T1/sl unknown
- 2013-06-12 PH PH1/2019/502809A patent/PH12019502809B1/en unknown
- 2013-06-12 CN CN201710395346.XA patent/CN107383009B/zh active Active
- 2013-06-12 KR KR1020157000701A patent/KR102140426B1/ko active IP Right Grant
- 2013-06-12 AR ARP130102068A patent/AR091424A1/es active IP Right Grant
- 2013-06-12 RS RS20190048A patent/RS58514B1/sr unknown
- 2013-06-12 ME MEP-2019-2A patent/ME03300B/me unknown
- 2013-06-12 LT LTEP13783125.1T patent/LT2861595T/lt unknown
- 2013-06-12 NZ NZ743274A patent/NZ743274A/en unknown
- 2013-06-12 ES ES16203866T patent/ES2704744T3/es active Active
- 2013-06-12 EP EP24164194.3A patent/EP4403216A3/en active Pending
- 2013-06-12 UA UAA201500191A patent/UA117347C2/uk unknown
- 2013-06-12 PL PL18198112T patent/PL3495367T3/pl unknown
- 2013-06-12 ES ES20192679T patent/ES2984771T3/es active Active
- 2013-06-12 HU HUE13783125A patent/HUE031916T2/en unknown
- 2013-06-12 HU HUE16203866A patent/HUE042374T2/hu unknown
- 2013-06-12 PE PE2014002433A patent/PE20150684A1/es active IP Right Grant
- 2013-06-12 HU HUE18198112A patent/HUE052195T2/hu unknown
- 2013-06-12 RS RS20201398A patent/RS61089B1/sr unknown
- 2013-06-12 PT PT181981127T patent/PT3495367T/pt unknown
- 2013-06-12 AU AU2013287176A patent/AU2013287176C1/en active Active
- 2013-06-12 LT LTEP18198112.7T patent/LT3495367T/lt unknown
- 2013-06-12 LT LTEP16203866.5T patent/LT3176170T/lt unknown
- 2013-06-12 PL PL16203866T patent/PL3176170T3/pl unknown
- 2013-06-12 CA CA3149881A patent/CA3149881A1/en active Pending
- 2013-06-12 KR KR1020207021884A patent/KR102406771B1/ko active IP Right Grant
- 2013-06-12 WO PCT/US2013/045309 patent/WO2014007951A2/en active Application Filing
- 2013-06-12 ES ES13783125T patent/ES2618003T3/es active Active
- 2013-06-12 DK DK13783125.1T patent/DK2861595T5/en active
- 2013-06-12 PT PT16203866T patent/PT3176170T/pt unknown
- 2013-06-12 BR BR112014030812-8A patent/BR112014030812B1/pt active IP Right Grant
- 2013-06-12 ES ES18198112T patent/ES2832497T3/es active Active
- 2013-06-12 EA EA201590005A patent/EA036592B1/ru unknown
- 2013-06-12 US US13/915,775 patent/US9611267B2/en active Active
- 2013-06-12 IL IL289834A patent/IL289834B2/en unknown
- 2013-06-12 SM SM20190040T patent/SMT201900040T1/it unknown
- 2013-06-12 DK DK18198112.7T patent/DK3495367T3/da active
- 2013-06-12 SM SM20170146T patent/SMT201700146T1/it unknown
- 2013-06-12 EP EP13783125.1A patent/EP2861595B9/en active Active
- 2013-06-12 CN CN201380041027.9A patent/CN104507943B/zh active Active
- 2013-06-12 JP JP2015517376A patent/JP6301321B2/ja active Active
- 2013-06-12 PL PL13783125T patent/PL2861595T3/pl unknown
- 2013-06-12 DK DK16203866.5T patent/DK3176170T3/en active
- 2013-06-12 NZ NZ702747A patent/NZ702747A/en unknown
- 2013-06-12 CA CA2876689A patent/CA2876689C/en active Active
- 2013-06-12 RS RS20170276A patent/RS55908B1/sr unknown
- 2013-06-12 EP EP20192679.7A patent/EP3822273B1/en active Active
- 2013-06-12 UA UAA201801562A patent/UA125503C2/uk unknown
- 2013-06-12 SG SG10201610416TA patent/SG10201610416TA/en unknown
- 2013-06-12 MX MX2014015192A patent/MX359293B/es active IP Right Grant
- 2013-06-12 PT PT137831251T patent/PT2861595T/pt unknown
- 2013-06-12 KR KR1020227018808A patent/KR102556118B1/ko active IP Right Grant
- 2013-06-13 TW TW102120946A patent/TWI706953B/zh active
- 2013-06-13 TW TW111107608A patent/TWI801156B/zh active
- 2013-06-13 TW TW109132389A patent/TWI769529B/zh active
2014
- 2014-12-04 IL IL236078A patent/IL236078B/en active IP Right Grant
- 2014-12-05 MY MYPI2018000373A patent/MY188363A/en unknown
- 2014-12-10 MX MX2022000517A patent/MX2022000517A/es unknown
- 2014-12-10 PH PH12014502772A patent/PH12014502772B1/en unknown
- 2014-12-10 CL CL2014003355A patent/CL2014003355A1/es unknown
- 2014-12-16 CO CO14275934A patent/CO7240375A2/es unknown
2015
- 2015-09-28 HK HK15109517.8A patent/HK1212326A1/xx unknown
2017
- 2017-01-18 US US15/408,768 patent/US10131667B2/en active Active
- 2017-03-16 HR HRP20170430TT patent/HRP20170430T1/hr unknown
- 2017-03-16 CY CY20171100335T patent/CY1118744T1/el unknown
- 2017-08-03 CL CL2017001984A patent/CL2017001984A1/es unknown
- 2017-08-21 JP JP2017158805A patent/JP6336665B2/ja active Active
2018
- 2018-01-17 IL IL256976A patent/IL256976B/en active IP Right Grant
- 2018-05-02 JP JP2018088682A patent/JP6545863B2/ja active Active
- 2018-10-05 US US16/152,827 patent/US20190127376A1/en not_active Abandoned
2019
- 2019-01-02 HR HRP20190007TT patent/HRP20190007T1/hr unknown
- 2019-01-07 AU AU2019200066A patent/AU2019200066B2/en active Active
- 2019-02-06 CY CY20191100164T patent/CY1121299T1/el unknown
- 2019-06-19 JP JP2019113954A patent/JP6711946B2/ja active Active
2020
- 2020-04-07 US US16/842,558 patent/US11053246B2/en active Active
- 2020-05-28 JP JP2020093529A patent/JP7200170B2/ja active Active
- 2020-08-02 IL IL276433A patent/IL276433B/en active IP Right Grant
- 2020-11-18 AU AU2020270520A patent/AU2020270520B2/en active Active
- 2020-12-08 HR HRP20201966TT patent/HRP20201966T1/hr unknown
- 2020-12-14 CY CY20201101183T patent/CY1123631T1/el unknown
2021
- 2021-04-25 IL IL282622A patent/IL282622B/en unknown
- 2021-06-02 US US17/337,027 patent/US11840534B2/en active Active
- 2021-09-09 HU HUS2100035C patent/HUS2100035I1/hu unknown
- 2021-09-09 NO NO2021034C patent/NO2021034I1/no unknown
- 2021-09-10 LT LTPA2021519C patent/LTC2861595I2/lt unknown
- 2021-09-10 LU LU00222C patent/LUC00222I2/en unknown
- 2021-09-10 CY CY2021026C patent/CY2021026I1/el unknown
- 2021-09-21 NL NL301131C patent/NL301131I2/nl unknown
2022
- 2022-12-01 EC ECSENADI202291792A patent/ECSP22091792A/es unknown
- 2022-12-21 JP JP2022204466A patent/JP7392096B2/ja active Active
- 2022-12-21 AU AU2022291504A patent/AU2022291504B2/en active Active
2023
- 2023-10-20 US US18/382,210 patent/US20240246974A1/en active Pending
- 2023-11-22 JP JP2023197898A patent/JP2024023367A/ja active Pending
2024
- 2024-10-30 AU AU2024227763A patent/AU2024227763A1/en active Pending

Also Published As

Publication number	Publication date
EP3822273A1 (en)	2021-05-19
AU2024227763A1 (en)	2025-01-02
SI2861595T1 (sl)	2017-04-26
CN107383009B (zh)	2020-06-09
CY1121299T1 (el)	2020-05-29
PH12019502809B1 (en)	2024-04-24
ES2618003T3 (es)	2017-06-20
HRP20190007T1 (hr)	2019-04-05
WO2014007951A3 (en)	2014-03-06
US20210380587A1 (en)	2021-12-09
RS58514B1 (sr)	2019-04-30
EP3495367B1 (en)	2020-09-30
IL289834B1 (en)	2024-03-01
US10131667B2 (en)	2018-11-20
PL2861595T3 (pl)	2017-06-30
PL3176170T3 (pl)	2019-05-31
JP2017222709A (ja)	2017-12-21
ME02651B (me)	2017-06-20
CY2021026I2 (el)	2021-12-31
JP2024023367A (ja)	2024-02-21
NL301131I1 (it)	2021-09-29
EP3495367A1 (en)	2019-06-12
TWI706953B (zh)	2020-10-11
CY1118744T1 (el)	2017-07-12
MX359293B (es)	2018-09-24
ES2832497T3 (es)	2021-06-10
EP2861595A2 (en)	2015-04-22
IL282622A (en)	2021-06-30
IL276433A (en)	2020-09-30
ES2618003T8 (es)	2021-08-24
CO7240375A2 (es)	2015-04-17
PL3495367T3 (pl)	2021-04-19
JP6545863B2 (ja)	2019-07-17
AR091424A1 (es)	2015-02-04
RS55908B1 (sr)	2017-09-29
PH12019502809A1 (en)	2021-07-26
IL256976A (en)	2018-03-29
IL282622B (en)	2022-02-01
CA2876689A1 (en)	2014-01-09
BR112014030812B1 (pt)	2022-11-08
DK2861595T5 (en)	2018-01-15
TW201402574A (zh)	2014-01-16
MX2014015192A (es)	2015-08-07
KR20150036044A (ko)	2015-04-07
US20190127376A1 (en)	2019-05-02
AU2020270520B2 (en)	2023-01-05
JP2018135377A (ja)	2018-08-30
TW202124382A (zh)	2021-07-01
UA125503C2 (uk)	2022-04-13
WO2014007951A2 (en)	2014-01-09
LT2861595T (lt)	2017-02-27
MX2022000517A (es)	2022-05-18
JP6336665B2 (ja)	2018-06-06
ES2704744T3 (es)	2019-03-19
AU2013287176C1 (en)	2023-01-19
PT3495367T (pt)	2020-11-12
LTPA2021519I1 (it)	2021-09-27
US20200377504A1 (en)	2020-12-03
LT3495367T (lt)	2021-02-25
KR102556118B1 (ko)	2023-07-19
KR102406771B1 (ko)	2022-06-13
SG11201408238WA (en)	2015-01-29
DK3495367T3 (da)	2020-11-16
MY188363A (en)	2021-12-04
EP3176170A1 (en)	2017-06-07
SMT201700146T1 (it)	2017-05-08
HUS2100035I1 (hu)	2021-10-28
HK1212326A1 (zh)	2016-06-10
TWI801156B (zh)	2023-05-01
BR112014030812A2 (pt)	2017-07-25
AU2022291504B2 (en)	2024-08-01
AU2019200066B2 (en)	2020-08-27
CL2017001984A1 (es)	2018-03-23
MY171375A (en)	2019-10-10
AU2019200066A1 (en)	2019-01-24
CN107652289B (zh)	2020-07-21
NO2021034I1 (no)	2021-09-09
EP2861595B1 (en)	2016-12-21
US20240246974A1 (en)	2024-07-25
SMT201900040T1 (it)	2019-05-10
HUE052195T2 (hu)	2021-04-28
CN107383009A (zh)	2017-11-24
EA201590005A1 (ru)	2015-05-29
JP7392096B2 (ja)	2023-12-05
EP3176170B1 (en)	2018-11-14
CY2021026I1 (el)	2021-12-31
UA117347C2 (uk)	2018-07-25
SI3495367T1 (sl)	2021-01-29
SG10201610416TA (en)	2017-01-27
CN104507943B (zh)	2017-11-21
TW202241898A (zh)	2022-11-01
NZ730134A (en)	2018-07-27
PH12014502772A1 (en)	2015-02-02
KR20200093696A (ko)	2020-08-05
LUC00222I2 (it)	2024-10-04
AU2013287176A1 (en)	2015-01-15
IL276433B (en)	2021-05-31
US20170137424A1 (en)	2017-05-18
ME03300B (me)	2019-07-20
ES2618003T9 (es)	2018-03-02
CL2014003355A1 (es)	2015-06-12
NZ743274A (en)	2019-07-26
RS61089B1 (sr)	2020-12-31
JP6711946B2 (ja)	2020-06-17
JP2023027344A (ja)	2023-03-01
IL236078A0 (en)	2015-02-01
PE20190736A1 (es)	2019-05-23
TWI769529B (zh)	2022-07-01
JP7200170B2 (ja)	2023-01-06
EP3822273B1 (en)	2024-04-10
CA2876689C (en)	2022-04-26
DK3176170T3 (en)	2019-01-28
CA3149881A1 (en)	2014-01-09
LTC2861595I2 (it)	2023-06-26
PH12014502772B1 (en)	2015-02-02
IL289834A (en)	2022-03-01
IL256976B (en)	2020-08-31
ES2984771T3 (es)	2024-10-31
PE20150684A1 (es)	2015-05-11
KR20220080213A (ko)	2022-06-14
HUE031916T2 (en)	2017-08-28
US11840534B2 (en)	2023-12-12
JP2019178156A (ja)	2019-10-17
AU2013287176B2 (en)	2018-10-04
CN107652289A (zh)	2018-02-02
JP6301321B2 (ja)	2018-03-28
DK2861595T3 (en)	2017-02-13
HRP20170430T1 (hr)	2017-06-16
HRP20201966T1 (hr)	2021-02-05
IL236078B (en)	2019-08-29
AU2022291504A1 (en)	2023-02-02
SI3176170T1 (sl)	2019-05-31
IL289834B2 (en)	2024-07-01
EP4403216A2 (en)	2024-07-24
KR102140426B1 (ko)	2020-08-04
LT3176170T (lt)	2019-04-25
NZ702747A (en)	2017-03-31
EP4403216A3 (en)	2024-10-16
EP2861595B9 (en)	2017-06-21
US20130338134A1 (en)	2013-12-19
US9611267B2 (en)	2017-04-04
HUE042374T2 (hu)	2019-06-28
EA036592B1 (ru)	2020-11-26
PT2861595T (pt)	2017-04-03
PT3176170T (pt)	2019-02-05
AU2020270520A1 (en)	2020-12-17
CN104507943A (zh)	2015-04-08
JP2020143142A (ja)	2020-09-10
JP2015521600A (ja)	2015-07-30
CY1123631T1 (el)	2022-03-24
ECSP22091792A (es)	2023-01-31
US11053246B2 (en)	2021-07-06
NL301131I2 (nl)	2021-10-25

Publication	Publication Date	Title
IL289834A (en)	2022-03-01	Conversion of tricyclic compounds as fgfr inhibitors
HRP20180450T1 (hr)	2018-06-01	Heterobiciklični spojevi kao inhibitori beta-laktamaze
HUE045663T2 (hu)	2020-01-28	Pteridinek, mint FGFR inhibitorok
LT2917217T (lt)	2017-07-25	Pakeistieji tricikliniai benzimidazolai kaip kinazės inhibitoriai
HK1206734A1 (en)	2016-01-15	Tricyclic compounds as kat ii inhibitors kat ii